Document_and_Entity_Informatio
Document and Entity Information | 3 Months Ended | |
Mar. 31, 2015 | Apr. 30, 2015 | |
Document Information [Line Items] | ||
Document Type | 10-Q | |
Amendment Flag | FALSE | |
Document Period End Date | 31-Mar-15 | |
Document Fiscal Year Focus | 2015 | |
Document Fiscal Period Focus | Q1 | |
Trading Symbol | BAX | |
Entity Registrant Name | BAXTER INTERNATIONAL INC | |
Entity Central Index Key | 10456 | |
Current Fiscal Year End Date | -19 | |
Entity Filer Category | Large Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 544,254,211 |
Condensed_Consolidated_Stateme
Condensed Consolidated Statements of Income (USD $) | 3 Months Ended | |
In Millions, except Per Share data, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Net sales | $3,764 | $3,848 |
Cost of sales | 1,963 | 1,957 |
Gross margin | 1,801 | 1,891 |
Marketing and administrative expenses | 1,015 | 910 |
Research and development expenses | 300 | 309 |
Net interest expense | 30 | 43 |
Other income, net | -74 | -24 |
Income from continuing operations before income taxes | 530 | 653 |
Income tax expense | 110 | 146 |
Income from continuing operations | 420 | 507 |
Income from discontinued operations, net of tax | 10 | 49 |
Net income | $430 | $556 |
Income from continuing operations per common share | ||
Basic | $0.77 | $0.93 |
Diluted | $0.76 | $0.92 |
Income from discontinued operations per common share | ||
Basic | $0.02 | $0.09 |
Diluted | $0.02 | $0.09 |
Net income per common share | ||
Basic | $0.79 | $1.02 |
Diluted | $0.78 | $1.01 |
Weighted-average number of common shares outstanding | ||
Basic | 543 | 542 |
Diluted | 548 | 548 |
Cash dividends declared per common share | $0.52 | $0.49 |
Condensed_Consolidated_Stateme1
Condensed Consolidated Statements of Comprehensive Income (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Net income | $430 | $556 |
Other comprehensive (loss) income, net of tax: | ||
Currency translation adjustments, net of tax (benefit) expense of ($109) and $4 for the three months ended March 31, 2015 and 2014, respectively | -1,138 | 6 |
Pension and other employee benefits, net of tax expense of $31 and $9 for the three months ended March 31, 2015 and 2014, respectively | 68 | 23 |
Hedging activities, net of tax (benefit) of ($7) and ($6) for the three months ended March 31, 2015 and 2014, respectively | -10 | -10 |
Other, net of tax expense of $9 and $3 for the three months ended March 31, 2015 and 2014, respectively | 21 | 11 |
Total other comprehensive (loss) income, net of tax | -1,059 | 30 |
Comprehensive (loss) income | ($629) | $586 |
Condensed_Consolidated_Stateme2
Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Tax (benefit) expense on currency translation adjustments | ($109) | $4 |
Tax expense pension and other employee benefits | 31 | 9 |
Tax expense (benefit) on hedging activities | -7 | -6 |
Tax (benefit) expense on Other | $9 | $3 |
Condensed_Consolidated_Balance
Condensed Consolidated Balance Sheets (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Millions, unless otherwise specified | ||
Current assets | ||
Cash and equivalents | $2,530 | $2,925 |
Accounts and other current receivables, net | 2,599 | 2,803 |
Inventories | 3,501 | 3,559 |
Prepaid expenses and other | 1,104 | 1,064 |
Total current assets | 9,734 | 10,351 |
Property, plant and equipment, net | 8,492 | 8,698 |
Other assets | ||
Goodwill | 3,694 | 3,874 |
Other intangible assets, net | 2,068 | 2,079 |
Other | 873 | 915 |
Total other assets | 6,635 | 6,868 |
Total assets | 24,861 | 25,917 |
Current liabilities | ||
Short-term debt | 2,151 | 913 |
Current maturities of long-term debt and lease obligations | 174 | 786 |
Accounts payable and accrued liabilities | 3,749 | 4,343 |
Total current liabilities | 6,074 | 6,042 |
Long-term debt and lease obligations | 7,680 | 7,606 |
Other long-term liabilities | 3,819 | 4,113 |
Commitments and contingencies | ||
Equity | ||
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2015 and 2014 | 683 | 683 |
Common stock in treasury, at cost, 139,644,913 shares in 2015 and 141,116,857 shares in 2014 | -7,890 | -7,993 |
Additional contributed capital | 5,822 | 5,853 |
Retained earnings | 13,352 | 13,227 |
Accumulated other comprehensive loss | -4,709 | -3,650 |
Total Baxter shareholders' equity | 7,258 | 8,120 |
Noncontrolling interests | 30 | 36 |
Total equity | 7,288 | 8,156 |
Total liabilities and equity | $24,861 | $25,917 |
Condensed_Consolidated_Balance1
Condensed Consolidated Balance Sheets (Parenthetical) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
Common stock, par value | $1 | $1 |
Common stock, authorized | 2,000,000,000 | 2,000,000,000 |
Common stock, issued | 683,494,944 | 683,494,944 |
Treasury stock, shares | 139,644,913 | 141,116,857 |
Condensed_Consolidated_Stateme3
Condensed Consolidated Statements of Cash Flows (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Cash flows from operations | ||
Net income | $430 | $556 |
Adjustments | ||
Depreciation and amortization | 247 | 236 |
Deferred income taxes | 46 | -17 |
Stock compensation | 39 | 31 |
Net periodic pension benefit and OPEB costs | 82 | 71 |
Other | -100 | 1 |
Changes in balance sheet items | ||
Accounts and other current receivables, net | 12 | 233 |
Inventories | -207 | -233 |
Accounts payable and accrued liabilities | -383 | -278 |
Business optimization and infusion pump payments | -23 | -45 |
Other | -47 | 4 |
Cash flows from operations | 96 | 559 |
Cash flows from investing activities | ||
Capital expenditures | -521 | -421 |
Acquisitions and investments, net of cash acquired | -235 | -59 |
Divestitures and other investing activities | -14 | 96 |
Cash flows from investing activities | -770 | -384 |
Cash flows from financing activities | ||
Issuances of debt | 900 | 32 |
Payments of obligations | -618 | -510 |
Increase in debt with original maturities of three months or less, net | 361 | |
Cash dividends on common stock | -282 | -266 |
Proceeds and realized excess tax benefits from stock issued under employee benefit plans | 48 | 138 |
Purchases of treasury stock | -250 | |
Other | -25 | 4 |
Cash flows from financing activities | 384 | -852 |
Effect of foreign exchange rate changes on cash and equivalents | -105 | -7 |
Decrease in cash and equivalents | -395 | -684 |
Cash and equivalents at beginning of period | 2,925 | 2,733 |
Cash and equivalents at end of period | $2,530 | $2,049 |
BASIS_OF_PRESENTATION
BASIS OF PRESENTATION | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
BASIS OF PRESENTATION | 1. BASIS OF PRESENTATION | ||||||||
The unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (the company or Baxter) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the company’s Annual Report on Form 10-K for the year ended December 31, 2014 (2014 Annual Report). | |||||||||
In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair statement of the interim periods. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The results of operations for the interim period are not necessarily indicative of the results of operations to be expected for the full year. | |||||||||
Certain reclassifications have been made to conform the prior period condensed consolidated financial statements to the current period presentation. | |||||||||
Prior to 2015, the company’s biosurgery products and services were reported in the BioScience segment. As a result of the planned spin-off of the biopharmaceuticals business, the company realigned its biosurgery products and services to the Medical Products segment. Effective January 1, 2015, the company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation. | |||||||||
Vaccines discontinued operations | |||||||||
In July 2014, the company entered into an agreement with Pfizer Inc. to sell its commercial vaccines business and committed to a plan to divest the remainder of its Vaccines franchise, which includes certain R&D programs. In December 2014, the company completed the divestiture of the commercial vaccines business. In the first quarter of 2015, the company recorded an after-tax gain of $9 million as a result of a purchase price adjustment. In December 2014, the company also entered into a separate agreement for the sale of the remainder of the Vaccines franchise. As a result of the divestitures, the operations and cash flows of the Vaccines franchise will be eliminated from the ongoing operations of the company. | |||||||||
Following is a summary of the operating results of the Vaccines franchise, which have been reflected as discontinued operations for the three months ended March 31, 2015 and 2014. | |||||||||
Three months ended | |||||||||
March 31, | |||||||||
(in millions) | 2015 | 2014 | |||||||
Net sales | $ 1 | $103 | |||||||
Income before income taxes | 11 | 56 | |||||||
Income tax expense | 1 | 7 | |||||||
Net income | $10 | $ 49 | |||||||
Planned spin-off of biopharmaceuticals business | |||||||||
In March 2014, Baxter announced plans to create two separate, independent global healthcare companies – one focused on developing and marketing innovative biopharmaceuticals and the other on life-saving medical products. The transaction is intended to take the form of a tax-free distribution in the United States to Baxter shareholders of more than 80% of the publicly traded stock in the new biopharmaceuticals company. The transaction is expected to be completed by mid-year 2015, subject to market, regulatory and certain other conditions, including final approval by the Baxter Board of Directors, receipt of a favorable opinion and/or rulings in the United States with respect to the tax-free nature of the transaction, and the effectiveness of a Form 10 registration statement that has been filed with the SEC. Upon separation, the historical results of the biopharmaceuticals business will be presented as discontinued operations. | |||||||||
New accounting standards | |||||||||
In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which amends the existing accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to customers. ASU No. 2014-09 will be effective for the company beginning on January 1, 2017. Early adoption is not permitted. The new revenue standard may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. In April 2015, the FASB issued an exposure draft that would delay the effective date of the standard by one year and allow early adoption as of the original effective date. The company is currently evaluating the impact of adopting the new revenue standard on its consolidated financial statements. |
SUPPLEMENTAL_FINANCIAL_INFORMA
SUPPLEMENTAL FINANCIAL INFORMATION | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
SUPPLEMENTAL FINANCIAL INFORMATION | 2. SUPPLEMENTAL FINANCIAL INFORMATION | ||||||||
Net interest expense | |||||||||
Three months ended | |||||||||
March 31, | |||||||||
(in millions) | 2015 | 2014 | |||||||
Interest expense, net of capitalized interest | $35 | $48 | |||||||
Interest income | (5 | ) | (5 | ) | |||||
Net interest expense | $30 | $43 | |||||||
Inventories | |||||||||
March 31, | December 31, | ||||||||
(in millions) | 2015 | 2014 | |||||||
Raw materials | $ 859 | $ 910 | |||||||
Work in process | 1,107 | 1,126 | |||||||
Finished goods | 1,535 | 1,523 | |||||||
Inventories | $3,501 | $3,559 | |||||||
Property, plant and equipment, net | |||||||||
March 31, | December 31, | ||||||||
(in millions) | 2015 | 2014 | |||||||
Property, plant and equipment, at cost | $14,366 | $14,808 | |||||||
Accumulated depreciation | (5,874 | ) | (6,110 | ) | |||||
Property, plant and equipment (PP&E), net | $ 8,492 | $ 8,698 | |||||||
EARNINGS_PER_SHARE
EARNINGS PER SHARE | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
EARNINGS PER SHARE | 3. EARNINGS PER SHARE | ||||||||
The numerator for both basic and diluted earnings per share (EPS) is either net income, income from continuing operations, or income from discontinued operations. The denominator for basic EPS is the weighted-average number of common shares outstanding during the period. The dilutive effect of outstanding stock options, restricted stock units (RSUs) and performance share units (PSUs) is reflected in the denominator for diluted EPS using the treasury stock method. | |||||||||
The following is a reconciliation of basic shares to diluted shares. | |||||||||
Three months ended | |||||||||
March 31, | |||||||||
(in millions) | 2015 | 2014 | |||||||
Basic shares | 543 | 542 | |||||||
Effect of dilutive securities | 5 | 6 | |||||||
Diluted shares | 548 | 548 | |||||||
The effect of dilutive securities included unexercised stock options, unvested RSUs and contingently issuable shares related to granted PSUs. The computation of diluted EPS excluded 9 million and 8 million equity awards for the first quarters of 2015 and 2014, respectively, because their inclusion would have had an anti-dilutive effect on diluted EPS. Refer to Note 8 and Note 10 for additional information regarding items impacting basic shares, including the company’s stock repurchase program. |
ACQUISITIONS_AND_COLLABORATION
ACQUISITIONS AND COLLABORATIONS | 3 Months Ended | ||||
Mar. 31, 2015 | |||||
ACQUISITIONS AND COLLABORATIONS | 4. ACQUISITIONS AND COLLABORATIONS | ||||
Acquisitions | |||||
In March 2015, Baxter acquired all of the outstanding shares of SuppreMol GmbH (SuppreMol), a privately held biopharmaceutical company based in Germany. Through the acquisition, Baxter acquired SuppreMol’s early-stage pipeline of treatment options for autoimmune and allergic diseases, as well as its operations in Munich, Germany. The acquired investigational treatments will complement and build upon Baxter’s immunology portfolio and offer an opportunity to expand into new areas with significant market potential and unmet medical needs in autoimmune diseases. | |||||
The following table summarizes the fair value of the consideration transferred and the recognized amounts of the assets acquired and liabilities assumed as of the acquisition date. | |||||
(in millions) | |||||
Consideration transferred | |||||
Cash, net of cash acquired | $228 | ||||
Fair value of consideration transferred | $228 | ||||
Assets acquired and liabilities assumed | |||||
Deferred tax asset | $ 17 | ||||
In-process research and development (IPR&D) | 179 | ||||
Other assets, net | 1 | ||||
Deferred tax liability | (52 | ) | |||
Total identifiable net assets | 145 | ||||
Goodwill | 83 | ||||
Total assets acquired and liabilities assumed | $228 | ||||
While the valuation of the assets acquired and liabilities assumed is substantially complete, measurement period adjustments may be recorded in the future as the company finalizes its fair value estimates. Pro forma financial information has not been provided because the pro forma impact of the acquisition was not material to the company’s condensed consolidated financial statements. | |||||
Baxter allocated $179 million of the consideration to acquired IPR&D, which is being accounted for as an indefinite-lived intangible asset. The acquired IPR&D relates to SuppreMol’s SM-101, an investigational immunoregulatory treatment, which had completed Phase IIa studies at the time of the acquisition and is expected to be completed in approximately 5 years. The value of the IPR&D was calculated using cash flow projections adjusted for the inherent technical, regulatory, commercial and obsolescence risks in such activities, discounted at a rate of 20%. Additional research and development will be required prior to regulatory approval, and as of the acquisition date, incremental research and development costs were projected to be in excess of $400 million. The goodwill, which is not deductible for tax purposes, includes the value of potential future technologies as well as the overall strategic benefits of the acquisition to Baxter’s immunology portfolio and is included in the BioScience segment. | |||||
Collaborations | |||||
Baxter recognized an R&D charge of $25 million for the first quarter of 2014 related to a milestone payment pursuant to the company’s collaboration arrangement with Coherus Biosciences, Inc. Refer to the 2014 Annual Report for further discussion of the company’s collaboration arrangements. |
GOODWILL_AND_OTHER_INTANGIBLE_
GOODWILL AND OTHER INTANGIBLE ASSETS, NET | 3 Months Ended | ||||||||||||||||
Mar. 31, 2015 | |||||||||||||||||
GOODWILL AND OTHER INTANGIBLE ASSETS, NET | 5. GOODWILL AND OTHER INTANGIBLE ASSETS, NET | ||||||||||||||||
Goodwill | |||||||||||||||||
The following is a reconciliation of goodwill by business segment. | |||||||||||||||||
(in millions) | BioScience | Medical Products | Total | ||||||||||||||
Balance as of December 31, 2014 | $ 947 | $2,927 | $3,874 | ||||||||||||||
Additions | 83 | — | 83 | ||||||||||||||
Currency translation and other adjustments | (27 | ) | (236 | ) | (263 | ) | |||||||||||
Balance as of March 31, 2015 | $1,003 | $2,691 | $3,694 | ||||||||||||||
The balance as of December 31, 2014 has been recast to reflect the realignment of the company’s biosurgery products and services from the BioScience segment to the Medical Products segment. | |||||||||||||||||
The addition in the first quarter of 2015 was related to the acquisition of SuppreMol and the overall decrease in goodwill was driven by currency translation adjustments (CTA). | |||||||||||||||||
As of March 31, 2015, there were no accumulated goodwill impairment losses. | |||||||||||||||||
Other intangible assets, net | |||||||||||||||||
The following is a summary of the company’s other intangible assets. | |||||||||||||||||
(in millions) | Developed technology, | Other amortized | Indefinite-lived | Total | |||||||||||||
including patents | intangible assets | intangible assets | |||||||||||||||
March 31, 2015 | |||||||||||||||||
Gross other intangible assets | $2,171 | $414 | $406 | $2,991 | |||||||||||||
Accumulated amortization | (778 | ) | (145 | ) | — | (923 | ) | ||||||||||
Other intangible assets, net | $1,393 | $269 | $406 | $2,068 | |||||||||||||
December 31, 2014 | |||||||||||||||||
Gross other intangible assets | $2,278 | $443 | $272 | $2,993 | |||||||||||||
Accumulated amortization | (769 | ) | (145 | ) | — | (914 | ) | ||||||||||
Other intangible assets, net | $1,509 | $298 | $272 | $2,079 | |||||||||||||
Intangible asset amortization expense was $48 million and $43 million in the first quarters of 2015 and 2014, respectively. The anticipated annual amortization expense for intangible assets recorded as of March 31, 2015 is $183 million in 2015, $181 million in 2016, $166 million in 2017, $161 million in 2018, $148 million in 2019 and $146 million in 2020. | |||||||||||||||||
The increase in other intangible assets, net from the IPR&D acquired in the acquisition of SuppreMol during the first quarter of 2015 was more than offset by the decrease from amortization expense and CTA. |
INFUSION_PUMP_AND_BUSINESS_OPT
INFUSION PUMP AND BUSINESS OPTIMIZATION CHARGES | 3 Months Ended | ||||
Mar. 31, 2015 | |||||
INFUSION PUMP AND BUSINESS OPTIMIZATION CHARGES | 6. INFUSION PUMP AND BUSINESS OPTIMIZATION CHARGES | ||||
Infusion pump charges | |||||
There were no significant updates related to the company’s infusion pump recall activities during the first quarter of 2015. Refer to the 2014 Annual Report for further information about the company’s infusion pump recall activities. | |||||
Business optimization charges | |||||
The company records charges from its business optimization initiatives primarily related to costs associated with optimizing the company’s overall cost structure on a global basis, as the company streamlined its international operations, rationalized its manufacturing facilities, enhanced its general and administrative infrastructure and realigned certain R&D activities. Refer to the 2014 Annual Report for further information about these charges. | |||||
In the first quarter of 2015, the company adjusted its previous estimates by $29 million. The adjustments were partially offset by additional business optimization charges of $18 million, which were primarily related to severance and employee-related costs. The business optimization items resulted in a net benefit of $7 million in cost of sales, a net charge of $2 million in marketing and administrative expenses, and a net benefit of $6 million in R&D expenses. | |||||
In the first quarter of 2014, the company recorded business optimization charges totaling $28 million (of which $8 million related to discontinued operations) primarily related to severance and employee-related costs, and inclusive of Gambro post-acquisition restructuring activities. The business optimization items resulted in charges of $4 million in cost of sales, $10 million in marketing and administrative expenses, and $6 million in R&D expenses. | |||||
The following table summarizes cash activity in the reserves related to the company’s business optimization initiatives. | |||||
(in millions) | |||||
Reserves as of December 31, 2014 | $ | 169 | |||
Charges | 16 | ||||
Reserve adjustments | (29 | ) | |||
Utilization | (20 | ) | |||
CTA | (9 | ) | |||
Reserves as of March 31, 2015 | $ | 127 | |||
The reserves are expected to be substantially utilized by the end of 2016. The company believes the remaining reserves to be adequate; however, additional adjustments may be recorded in the future as the programs are completed. |
DEBT_FINANCIAL_INSTRUMENTS_AND
DEBT, FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS | 3 Months Ended | ||||||||||||||||||||
Mar. 31, 2015 | |||||||||||||||||||||
DEBT, FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS | 7. DEBT, FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS | ||||||||||||||||||||
Securitization arrangement | |||||||||||||||||||||
The following is a summary of the activity relating to the company’s securitization arrangement in Japan. | |||||||||||||||||||||
Three months ended | |||||||||||||||||||||
March 31, | |||||||||||||||||||||
(in millions) | 2015 | 2014 | |||||||||||||||||||
Sold receivables at beginning of period | $104 | $114 | |||||||||||||||||||
Proceeds from sales of receivables | 113 | 123 | |||||||||||||||||||
Cash collections (remitted to the owners of the receivables) | (120 | ) | (129 | ) | |||||||||||||||||
Effect of currency exchange rate changes | (1 | ) | 1 | ||||||||||||||||||
Sold receivables at end of period | $ 96 | $109 | |||||||||||||||||||
The net losses relating to the sales of receivables were immaterial for each period. Refer to the 2014 Annual Report for further information regarding the company’s securitization agreements. | |||||||||||||||||||||
Credit facilities and commercial paper | |||||||||||||||||||||
In the first quarter of 2015, the company borrowed $900 million under one of its U.S. dollar-denominated revolving credit facilities at an interest rate of 1.27%. As of March 31, 2015, the $900 million balance was outstanding. This facility matures in December 2015. As of December 31, 2014 there were no borrowings under any of the company’s credit facilities. Refer to the 2014 Annual Report for further discussion of the company’s credit facilities. | |||||||||||||||||||||
During the first quarter of 2015, the company issued and redeemed commercial paper. There was a balance of $1.2 billion outstanding at March 31, 2015 with a weighted-average interest rate of 0.66% and a balance of $875 million outstanding at December 31, 2014 with a weighted-average interest rate of 0.46%. | |||||||||||||||||||||
Concentrations of credit risk | |||||||||||||||||||||
The company invests excess cash in certificates of deposit or money market funds and diversifies the concentration of cash among different financial institutions. With respect to financial instruments, where appropriate, the company has diversified its selection of counterparties, and has arranged collateralization and master-netting agreements to minimize the risk of loss. | |||||||||||||||||||||
The company continues to do business with foreign governments in certain countries, including Greece, Spain, Portugal and Italy, that have experienced a deterioration in credit and economic conditions. As of March 31, 2015, the company’s net accounts receivable from the public sector in Greece, Spain, Portugal and Italy totaled $328 million. | |||||||||||||||||||||
Global economic conditions and liquidity issues in certain countries have resulted, and may continue to result, in delays in the collection of receivables and credit losses. Governmental actions and customer-specific factors may also require the company to re-evaluate the collectibility of its receivables and the company could potentially incur additional credit losses. These conditions may also impact the stability of the Euro. | |||||||||||||||||||||
Derivatives and hedging activities | |||||||||||||||||||||
The company operates on a global basis and is exposed to the risk that its earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange and interest rates. The company’s hedging policy attempts to manage these risks to an acceptable level based on the company’s judgment of the appropriate trade-off between risk, opportunity and costs. | |||||||||||||||||||||
The company is primarily exposed to foreign exchange risk with respect to recognized assets and liabilities, forecasted transactions and net assets denominated in the Euro, Japanese Yen, British Pound, Australian Dollar, Canadian Dollar, Brazilian Real, Colombian Peso, and Swedish Krona. The company manages its foreign currency exposures on a consolidated basis, which allows the company to net exposures and take advantage of any natural offsets. In addition, the company uses derivative and nonderivative instruments to further reduce the net exposure to foreign exchange. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and equity volatility resulting from foreign exchange. Financial market and currency volatility may limit the company’s ability to cost-effectively hedge these exposures. | |||||||||||||||||||||
The company is also exposed to the risk that its earnings and cash flows could be adversely impacted by fluctuations in interest rates. The company’s policy is to manage interest costs using a mix of fixed- and floating-rate debt that the company believes is appropriate. To manage this mix in a cost-efficient manner, the company periodically enters into interest rate swaps in which the company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount. | |||||||||||||||||||||
The company does not hold any instruments for trading purposes and none of the company’s outstanding derivative instruments contain credit-risk-related contingent features. | |||||||||||||||||||||
All derivative instruments are recognized as either assets or liabilities at fair value in the condensed consolidated balance sheets and are classified as short-term or long-term based on the scheduled maturity of the instrument. Based upon the exposure being hedged, the company designates its hedging instruments as cash flow or fair value hedges. | |||||||||||||||||||||
Cash Flow Hedges | |||||||||||||||||||||
The company may use options, including collars and purchased options, forwards and cross-currency swaps to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. The company periodically uses forward-starting interest rate swaps and treasury rate locks to hedge the risk to earnings associated with movements in interest rates relating to anticipated issuances of debt. Certain other firm commitments and forecasted transactions are also periodically hedged. | |||||||||||||||||||||
For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is accumulated in accumulated other comprehensive income (AOCI) and then recognized in earnings consistent with the underlying hedged item. Option premiums or net premiums paid are initially recorded as assets and reclassified to other comprehensive income (OCI) over the life of the option, and then recognized in earnings consistent with the underlying hedged item. Cash flow hedges are classified in net sales, cost of sales, and net interest expense, and primarily relate to forecasted third-party sales denominated in foreign currencies, forecasted intercompany sales denominated in foreign currencies, and anticipated issuances of debt, respectively. | |||||||||||||||||||||
The notional amounts of foreign exchange contracts were $703 million and $917 million as of March 31, 2015 and December 31, 2014, respectively. The notional amounts of interest rate contracts were $1.8 billion and $550 million as of March 31, 2015 and December 31, 2014, respectively. The maximum term over which the company has cash flow hedge contracts in place related to forecasted transactions as of March 31, 2015 is 12 months. | |||||||||||||||||||||
Fair Value Hedges | |||||||||||||||||||||
The company uses interest rate swaps to convert a portion of its fixed-rate debt into variable-rate debt. These instruments hedge the company’s earnings from changes in the fair value of debt due to fluctuations in the designated benchmark interest rate. For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the derivative is recognized immediately to earnings, and offsets the loss or gain on the underlying hedged item. Fair value hedges are classified in net interest expense, as they hedge the interest rate risk associated with certain of the company’s fixed-rate debt. | |||||||||||||||||||||
The total notional amount of interest rate contracts designated as fair value hedges was $2.9 billion as of both March 31, 2015 and December 31, 2014. | |||||||||||||||||||||
Dedesignations | |||||||||||||||||||||
If it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, the company discontinues hedge accounting prospectively. If the company removes the cash flow hedge designation because the hedged forecasted transactions are no longer probable of occurring, any gains or losses are immediately reclassified from AOCI to earnings. Gains or losses relating to terminations of effective cash flow hedges in which the forecasted transactions are still probable of occurring are deferred and recognized consistent with the loss or income recognition of the underlying hedged items. | |||||||||||||||||||||
There were no hedge dedesignations in the first three months of 2015 or 2014 resulting from changes in the company’s assessment of the probability that the hedged forecasted transactions would occur. | |||||||||||||||||||||
If the company terminates a fair value hedge, an amount equal to the cumulative fair value adjustment to the hedged items at the date of termination is amortized to earnings over the remaining term of the hedged item. There were no fair value hedges terminated during the first three months of 2015 and 2014. | |||||||||||||||||||||
Undesignated Derivative Instruments | |||||||||||||||||||||
The company uses forward contracts to hedge earnings from the effects of foreign exchange relating to certain of the company’s intercompany and third-party receivables and payables denominated in a foreign currency. These derivative instruments are generally not formally designated as hedges, and the change in fair value, which substantially offsets the change in book value of the hedged items, is recorded directly to other income, net. The terms of these instruments generally do not exceed one month. | |||||||||||||||||||||
The total notional amount of undesignated derivative instruments was $459 million as of March 31, 2015 and $434 million as of December 31, 2014. | |||||||||||||||||||||
Gains and Losses on Derivative Instruments | |||||||||||||||||||||
The following table summarizes the income statement locations and gains and losses on the company’s derivative instruments for the three months ended March 31, 2015 and 2014. | |||||||||||||||||||||
Gain (loss) recognized in OCI | Location of gain (loss) | Gain (loss) reclassified from AOCI | |||||||||||||||||||
into income | |||||||||||||||||||||
(in millions) | 2015 | 2014 | in income statement | 2015 | 2014 | ||||||||||||||||
Cash flow hedges | |||||||||||||||||||||
Interest rate contracts | $(55 | ) | $ — | Net interest expense | $— | $(1 | ) | ||||||||||||||
Foreign exchange contracts | (1 | ) | (1 | ) | Net sales | — | — | ||||||||||||||
Foreign exchange contracts | 64 | (11 | ) | Cost of sales | 25 | 5 | |||||||||||||||
Total | $ 8 | $(12 | ) | $25 | $ 4 | ||||||||||||||||
Gain (loss) recognized in income | |||||||||||||||||||||
(in millions) | Location of gain (loss) in income statement | 2015 | 2014 | ||||||||||||||||||
Fair value hedges | |||||||||||||||||||||
Interest rate contracts | Net interest expense | $47 | $14 | ||||||||||||||||||
Undesignated derivative instruments | |||||||||||||||||||||
Foreign exchange contracts | Other income, net | $ (8 | ) | $12 | |||||||||||||||||
For the company’s fair value hedges, equal and offsetting losses of $47 million and $14 million were recognized in net interest expense in the first quarters of 2015 and 2014, respectively, as adjustments to the underlying hedged item, fixed-rate debt. Ineffectiveness related to the company’s cash flow and fair value hedges for the first quarter of 2015 was not material. | |||||||||||||||||||||
As of March 31, 2015, $52 million of deferred, net after-tax gains on derivative instruments included in AOCI are expected to be recognized in earnings during the next 12 months, coinciding with when the hedged items are expected to impact earnings. | |||||||||||||||||||||
Fair Values of Derivative Instruments | |||||||||||||||||||||
The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of March 31, 2015. | |||||||||||||||||||||
Derivatives in asset positions | Derivatives in liability positions | ||||||||||||||||||||
(in millions) | Balance sheet location | Fair value | Balance sheet location | Fair value | |||||||||||||||||
Derivative instruments designated as hedges | |||||||||||||||||||||
Interest rate contracts | Prepaid expenses and other | $ — | Accounts payable and | $56 | |||||||||||||||||
accrued liabilities | |||||||||||||||||||||
Interest rate contracts | Other long-term assets | 136 | Other long-term liabilities | — | |||||||||||||||||
Foreign exchange contracts | Prepaid expenses and other | 79 | Accounts payable | — | |||||||||||||||||
and accrued liabilities | |||||||||||||||||||||
Total derivative instruments designated as hedges | $215 | $56 | |||||||||||||||||||
Undesignated derivative instruments | |||||||||||||||||||||
Foreign exchange contracts | Prepaid expenses and other | $ — | Accounts payable | $ 2 | |||||||||||||||||
and accrued liabilities | |||||||||||||||||||||
Total derivative instruments | $215 | $58 | |||||||||||||||||||
The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2014. | |||||||||||||||||||||
Derivatives in asset positions | Derivatives in liability positions | ||||||||||||||||||||
(in millions) | Balance sheet location | Fair value | Balance sheet location | Fair value | |||||||||||||||||
Derivative instruments designated as hedges | |||||||||||||||||||||
Interest rate contracts | Prepaid expenses and other | $ 1 | Accounts payable | $ 2 | |||||||||||||||||
and accrued liabilities | |||||||||||||||||||||
Interest rate contracts | Other long-term assets | 89 | Other long-term liabilities | — | |||||||||||||||||
Foreign exchange contracts | Prepaid expenses and other | 51 | Accounts payable | — | |||||||||||||||||
and accrued liabilities | |||||||||||||||||||||
Total derivative instruments designated as hedges | $141 | $ 2 | |||||||||||||||||||
Undesignated derivative instruments | |||||||||||||||||||||
Foreign exchange contracts | Prepaid expenses and other | $ — | Accounts payable | $23 | |||||||||||||||||
and accrued liabilities | |||||||||||||||||||||
Total derivative instruments | $141 | $25 | |||||||||||||||||||
While the company’s derivatives are all subject to master netting arrangements, the company presents its assets and liabilities related to derivative instruments on a gross basis within the condensed consolidated balance sheets. Additionally, the company is not required to post collateral for any of its outstanding derivatives. | |||||||||||||||||||||
The following table provides information on the company’s derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty. | |||||||||||||||||||||
March 31, 2015 | December 31, 2014 | ||||||||||||||||||||
(in millions) | Asset | Liability | Asset | Liability | |||||||||||||||||
Gross amounts recognized in the consolidated balance sheet | $215 | $58 | $141 | $25 | |||||||||||||||||
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet | (58 | ) | (58 | ) | (22 | ) | (22 | ) | |||||||||||||
Total | $157 | $— | $119 | $ 3 | |||||||||||||||||
Fair value measurements | |||||||||||||||||||||
The following tables summarize the bases used to measure financial assets and liabilities that are carried at fair value on a recurring basis in the condensed consolidated balance sheets. | |||||||||||||||||||||
Basis of fair value measurement | |||||||||||||||||||||
(in millions) | Balance as of | Quoted prices in | Significant other | Significant | |||||||||||||||||
active markets for | observable inputs | unobservable | |||||||||||||||||||
March 31, 2015 | identical assets | ||||||||||||||||||||
(Level 2) | inputs | ||||||||||||||||||||
(Level 1) | |||||||||||||||||||||
(Level 3) | |||||||||||||||||||||
Assets | |||||||||||||||||||||
Foreign currency hedges | $ 79 | $ — | $ 79 | $ — | |||||||||||||||||
Interest rate hedges | 136 | — | 136 | — | |||||||||||||||||
Available-for-sale securities | |||||||||||||||||||||
Equity securities | 120 | 120 | — | — | |||||||||||||||||
Foreign government debt securities | 15 | — | 15 | — | |||||||||||||||||
Total assets | $350 | $120 | $230 | $ — | |||||||||||||||||
Liabilities | |||||||||||||||||||||
Foreign currency hedges | $ 2 | $ — | $ 2 | $ — | |||||||||||||||||
Interest rate hedges | 56 | — | 56 | — | |||||||||||||||||
Contingent payments related to acquisitions | 541 | — | — | 541 | |||||||||||||||||
Total liabilities | $599 | $ — | $ 58 | $541 | |||||||||||||||||
Basis of fair value measurement | |||||||||||||||||||||
(in millions) | Balance as of | Quoted prices in | Significant other | Significant | |||||||||||||||||
active markets for | observable inputs | unobservable | |||||||||||||||||||
December 31, 2014 | identical assets | ||||||||||||||||||||
(Level 2) | inputs | ||||||||||||||||||||
(Level 1) | |||||||||||||||||||||
(Level 3) | |||||||||||||||||||||
Assets | |||||||||||||||||||||
Foreign currency hedges | $ 51 | $ — | $ 51 | $ — | |||||||||||||||||
Interest rate hedges | 90 | — | 90 | — | |||||||||||||||||
Available-for-sale securities | |||||||||||||||||||||
Equity securities | 105 | 105 | — | — | |||||||||||||||||
Foreign government debt securities | 18 | — | 18 | — | |||||||||||||||||
Total assets | $264 | $105 | $159 | $ — | |||||||||||||||||
Liabilities | |||||||||||||||||||||
Foreign currency hedges | $ 23 | $ — | $ 23 | $ — | |||||||||||||||||
Interest rate hedges | 2 | — | 2 | — | |||||||||||||||||
Contingent payments related to acquisitions | 569 | — | — | 569 | |||||||||||||||||
Total liabilities | $594 | $ — | $ 25 | $569 | |||||||||||||||||
As of March 31, 2015, cash and equivalents of $2.5 billion included money market funds of approximately $196 million, and as of December 31, 2014, cash and equivalents of $2.9 billion included money market funds of approximately $989 million. Money market funds would be considered Level 2 in the fair value hierarchy. | |||||||||||||||||||||
For assets that are measured using quoted prices in active markets, the fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The majority of the derivatives entered into by the company are valued using internal valuation techniques as no quoted market prices exist for such instruments. The principal techniques used to value these instruments are discounted cash flow and Black-Scholes models. The key inputs are considered observable and vary depending on the type of derivative, and include contractual terms, interest rate yield curves, foreign exchange rates and volatility. The fair values of foreign government debt securities are obtained from pricing services or broker/dealers who use proprietary pricing applications, which include observable market information for like or same securities. | |||||||||||||||||||||
Contingent payments related to acquisitions consist of development, regulatory, and commercial milestone payments, in addition to sales-based payments, and are valued using discounted cash flow techniques. The fair value of development, regulatory, and commercial milestone payments reflects management’s expectations of probability of payment, and increases or decreases as the probability of payment or expectation of timing of payments changes. As of March 31, 2015, management’s expected weighted-average probability of payment for development and commercial milestone payments was approximately 26%. The fair value of sales-based payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes. | |||||||||||||||||||||
At March 31, 2015, the company held available-for-sale equity securities that had an amortized cost basis and fair value of $63 million and $120 million, respectively. The company had net unrealized gains of $57 million, comprised of unrealized losses of $1 million, which the company believes to be temporary in nature, and unrealized gains of $58 million. In the first quarter of 2015, the company recorded $9 million in other-than-temporary impairment charges based on the duration of losses related to two of the company’s investments. At December 31, 2014, the amortized cost basis and fair value of the available-for-sale equity securities was $79 million and $105 million, respectively. The company had net unrealized gains of $26 million, comprised of unrealized losses of $9 million, which the company believes to be temporary in nature, and unrealized gains of $35 million. | |||||||||||||||||||||
Changes in the fair value of contingent payments related to acquisitions, which use significant unobservable inputs (Level 3) in the fair value measurement, were immaterial during the period. | |||||||||||||||||||||
Book Values and Fair Values of Financial Instruments | |||||||||||||||||||||
In addition to the financial instruments that the company is required to recognize at fair value in the condensed consolidated balance sheets, the company has certain financial instruments that are recognized at historical cost or some basis other than fair value. For these financial instruments, the following table provides the values recognized in the condensed consolidated balance sheets and the approximate fair values as of March 31, 2015 and December 31, 2014. | |||||||||||||||||||||
Book values | Approximate fair values | ||||||||||||||||||||
(in millions) | 2015 | 2014 | 2015 | 2014 | |||||||||||||||||
Assets | |||||||||||||||||||||
Investments | $ 59 | $ 54 | $ 59 | $ 52 | |||||||||||||||||
Liabilities | |||||||||||||||||||||
Short-term debt | 2,151 | 913 | 2,151 | 913 | |||||||||||||||||
Current maturities of long-term debt and lease obligations | 174 | 786 | 174 | 791 | |||||||||||||||||
Long-term debt and lease obligations | 7,680 | 7,606 | 8,235 | 8,192 | |||||||||||||||||
Long-term litigation liabilities | 48 | 53 | 47 | 52 | |||||||||||||||||
The following tables summarize the bases used to measure the approximate fair value of the financial instruments as of March 31, 2015 and December 31, 2014. | |||||||||||||||||||||
Basis of fair value measurement | |||||||||||||||||||||
(in millions) | Fair value as of | Quoted prices in | Significant other | Significant | |||||||||||||||||
active markets for | observable inputs | unobservable | |||||||||||||||||||
March 31, 2015 | identical assets | ||||||||||||||||||||
(Level 2) | inputs | ||||||||||||||||||||
(Level 1) | |||||||||||||||||||||
(Level 3) | |||||||||||||||||||||
Assets | |||||||||||||||||||||
Investments | $ 59 | $— | $ 10 | $49 | |||||||||||||||||
Total assets | $ 59 | $— | $10 | $49 | |||||||||||||||||
Liabilities | |||||||||||||||||||||
Short-term debt | $ 2,151 | $— | $ 2,151 | $— | |||||||||||||||||
Current maturities of long-term debt and lease obligations | 174 | — | 174 | — | |||||||||||||||||
Long-term debt and lease obligations | 8,235 | — | 8,235 | — | |||||||||||||||||
Long-term litigation liabilities | 47 | — | — | 47 | |||||||||||||||||
Total liabilities | $10,607 | $— | $10,560 | $47 | |||||||||||||||||
Basis of fair value measurement | |||||||||||||||||||||
(in millions) | Fair value as of | Quoted prices in | Significant other | Significant | |||||||||||||||||
active markets for | observable inputs | unobservable | |||||||||||||||||||
December 31, 2014 | identical assets | ||||||||||||||||||||
(Level 2) | inputs | ||||||||||||||||||||
(Level 1) | |||||||||||||||||||||
(Level 3) | |||||||||||||||||||||
Assets | |||||||||||||||||||||
Investments | $ 52 | $— | $ 8 | $44 | |||||||||||||||||
Total assets | $ 52 | $— | $ 8 | $44 | |||||||||||||||||
Liabilities | |||||||||||||||||||||
Short-term debt | $ 913 | $— | $ 913 | $— | |||||||||||||||||
Current maturities of long-term debt and lease obligations | 791 | — | 791 | — | |||||||||||||||||
Long-term debt and lease obligations | 8,192 | — | 8,192 | — | |||||||||||||||||
Long-term litigation liabilities | 52 | — | — | 52 | |||||||||||||||||
Total liabilities | $9,948 | $— | $9,896 | $52 | |||||||||||||||||
The estimated fair values of long-term litigation liabilities were computed by discounting the expected cash flows based on currently available information, which in many cases does not include final orders or settlement agreements. The discount factors used in the calculations reflect the non-performance risk of the company. | |||||||||||||||||||||
Investments in 2015 and 2014 included certain cost method investments and held-to-maturity debt securities. | |||||||||||||||||||||
The fair value of held-to-maturity debt securities is calculated using a discounted cash flow model that incorporates observable inputs, including interest rate yields, which represents a Level 2 basis of fair value measurement. | |||||||||||||||||||||
In determining the fair value of cost method investments, the company takes into consideration recent transactions, as well as the financial information of the investee, which represents a Level 3 basis of fair value measurement. | |||||||||||||||||||||
The estimated fair values of current and long-term debt were computed by multiplying price by the notional amount of the respective debt instrument. Price is calculated using the stated terms of the respective debt instrument and yield curves commensurate with the company’s credit risk. The carrying values of the other financial instruments approximate their fair values due to the short-term maturities of most of these assets and liabilities. | |||||||||||||||||||||
In connection with the company’s initiative to invest in early-stage products and therapies, the company increased its unfunded commitments as a limited partner in multiple investment companies to $85 million as of March 31, 2015 from $38 million as of December 31, 2014. | |||||||||||||||||||||
In the first quarter of 2014, the company recorded $44 million of income in other income, net related to equity method investments, which primarily represented gains from the sale of certain investments as well as distributions from funds that sold portfolio companies. |
STOCK_COMPENSATION
STOCK COMPENSATION | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
STOCK COMPENSATION | 8. STOCK COMPENSATION | ||||||||
Stock compensation expense totaled $39 million and $31 million in the first quarter of 2015 and 2014, respectively. Over 70% of stock compensation expense is classified in marketing and administrative expenses with the remainder classified in cost of sales and R&D expenses. | |||||||||
In March 2015, the company awarded its annual stock compensation grants, which consisted of 8.8 million stock options and 1.3 million RSUs. | |||||||||
Stock Options | |||||||||
The weighted-average Black-Scholes assumptions used in estimating the fair value of stock options granted during the period, along with the weighted-average grant-date fair values, were as follows. | |||||||||
Three months ended | |||||||||
March 31, | |||||||||
2015 | 2014 | ||||||||
Expected volatility | 20% | 24% | |||||||
Expected life (in years) | 5.5 | 5.5 | |||||||
Risk-free interest rate | 1.70% | 1.70% | |||||||
Dividend yield | 3.00% | 2.80% | |||||||
Fair value per stock option | $9 | $12 | |||||||
The total intrinsic value of stock options exercised was $14 million and $45 million during the first quarters of 2015 and 2014, respectively. | |||||||||
As of March 31, 2015, the unrecognized compensation cost related to all unvested stock options of $120 million is expected to be recognized as expense over a weighted-average period of 2.1 years. | |||||||||
Restricted Stock Units | |||||||||
As of March 31, 2015, the unrecognized compensation cost related to all unvested RSUs of $154 million is expected to be recognized as expense over a weighted-average period of 2.1 years. | |||||||||
Performance Share Units | |||||||||
As of March 31, 2015, the unrecognized compensation cost related to all granted unvested PSUs of $17 million is expected to be recognized as expense over a weighted-average period of 1.2 years. |
RETIREMENT_AND_OTHER_BENEFIT_P
RETIREMENT AND OTHER BENEFIT PROGRAMS | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
RETIREMENT AND OTHER BENEFIT PROGRAMS | 9. RETIREMENT AND OTHER BENEFIT PROGRAMS | ||||||||
The following is a summary of net periodic benefit cost relating to the company’s pension and other postemployment benefit (OPEB) plans. | |||||||||
Three months ended | |||||||||
March 31, | |||||||||
(in millions) | 2015 | 2014 | |||||||
Pension benefits | |||||||||
Service cost | $37 | $33 | |||||||
Interest cost | 55 | 60 | |||||||
Expected return on plan assets | (67 | ) | (66 | ) | |||||
Amortization of net losses and other deferred amounts | 51 | 36 | |||||||
Net periodic pension benefit cost | $76 | $63 | |||||||
OPEB | |||||||||
Service cost | $ 1 | $ 1 | |||||||
Interest cost | 6 | 7 | |||||||
Amortization of net loss and prior service credit | (1 | ) | — | ||||||
Net periodic OPEB cost | $ 6 | $ 8 | |||||||
SHAREHOLDERS_EQUITY
SHAREHOLDERS' EQUITY | 3 Months Ended | ||||||||||||||||||||
Mar. 31, 2015 | |||||||||||||||||||||
SHAREHOLDERS' EQUITY | 10. SHAREHOLDERS’ EQUITY | ||||||||||||||||||||
Stock repurchases | |||||||||||||||||||||
In July 2012, the Board of Directors authorized the repurchase of up to $2.0 billion of the company’s common stock. During the first quarter of 2015, the company did not repurchase any shares and has $0.5 billion remaining available under the authorization as of March 31, 2015. | |||||||||||||||||||||
Accumulated other comprehensive income | |||||||||||||||||||||
Comprehensive income includes all changes in shareholders’ equity that do not arise from transactions with shareholders, and consists of net income, CTA, pension and other employee benefits, unrealized gains and losses on cash flow hedges and unrealized gains and losses on unrestricted available-for-sale marketable equity securities. The following is a net-of-tax summary of the changes in AOCI by component for the three months ended March 31, 2015 and 2014. | |||||||||||||||||||||
(in millions) | CTA | Pension and | Hedging | Other | Total | ||||||||||||||||
other employee | activities | ||||||||||||||||||||
benefits | |||||||||||||||||||||
Gains (losses) | |||||||||||||||||||||
Balance as of December 31, 2014 | $(2,323 | ) | $(1,427 | ) | $34 | $66 | $(3,650 | ) | |||||||||||||
Other comprehensive income before reclassifications | (1,138 | ) | 33 | 6 | 14 | (1,085 | ) | ||||||||||||||
Amounts reclassified from AOCI (a) | — | 35 | (16 | ) | 7 | 26 | |||||||||||||||
Net other comprehensive (loss) income | (1,138 | ) | 68 | (10 | ) | 21 | (1,059 | ) | |||||||||||||
Balance as of March 31, 2015 | $(3,461 | ) | $(1,359 | ) | $24 | $87 | $(4,709 | ) | |||||||||||||
(in millions) | CTA | Pension and | Hedging | Other | Total | ||||||||||||||||
other employee | activities | ||||||||||||||||||||
benefits | |||||||||||||||||||||
Gains (losses) | |||||||||||||||||||||
Balance as of December 31, 2013 | $ (991 | ) | $(1,027 | ) | $10 | $32 | $(1,976 | ) | |||||||||||||
Other comprehensive income before reclassifications | 6 | (3 | ) | (8 | ) | 11 | 6 | ||||||||||||||
Amounts reclassified from AOCI (a) | — | 26 | (2 | ) | — | 24 | |||||||||||||||
Net other comprehensive income (loss) | 6 | 23 | (10 | ) | 11 | 30 | |||||||||||||||
Balance as of March 31, 2014 | $ (985 | ) | $(1,004 | ) | $— | $43 | $(1,946 | ) | |||||||||||||
(a) | See table below for details about these reclassifications. | ||||||||||||||||||||
The following is a summary of the amounts reclassified from AOCI to net income during the three months ended March 31, 2015 and 2014. | |||||||||||||||||||||
Amount | |||||||||||||||||||||
reclassified | |||||||||||||||||||||
from AOCI (a) | |||||||||||||||||||||
(in millions) | 2015 | Location of impact in income statement | |||||||||||||||||||
Amortization of pension and other employee benefits items | |||||||||||||||||||||
Actuarial losses and other | $(50 | )(b) | |||||||||||||||||||
(50 | ) | Total before tax | |||||||||||||||||||
15 | Tax benefit | ||||||||||||||||||||
$(35 | ) | Net of tax | |||||||||||||||||||
Gains (losses) on hedging activities | |||||||||||||||||||||
Interest rate contracts | $ — | Net interest expense | |||||||||||||||||||
Foreign exchange contracts | — | Net sales | |||||||||||||||||||
Foreign exchange contracts | 25 | Cost of sales | |||||||||||||||||||
25 | Total before tax | ||||||||||||||||||||
(9 | ) | Tax expense | |||||||||||||||||||
$ 16 | Net of tax | ||||||||||||||||||||
Other | |||||||||||||||||||||
Other-than-temporary impairment of available-for-sale equity securities | $ (9 | ) | Other income, net | ||||||||||||||||||
(9 | ) | Total before tax | |||||||||||||||||||
2 | Tax benefit | ||||||||||||||||||||
$ (7 | ) | Net of tax | |||||||||||||||||||
Total reclassification for the period | $(26 | ) | Total net of tax | ||||||||||||||||||
Amount | |||||||||||||||||||||
reclassified | |||||||||||||||||||||
from AOCI (a) | |||||||||||||||||||||
(in millions) | 2014 | Location of impact in income statement | |||||||||||||||||||
Amortization of pension and other employee benefits items | |||||||||||||||||||||
Actuarial losses and other | $(36 | )(b) | |||||||||||||||||||
(36 | ) | Total before tax | |||||||||||||||||||
10 | Tax benefit | ||||||||||||||||||||
$(26 | ) | Net of tax | |||||||||||||||||||
Gains on hedging activities | |||||||||||||||||||||
Interest rate contracts | $ (1 | ) | Net interest expense | ||||||||||||||||||
Foreign exchange contracts | — | Net sales | |||||||||||||||||||
Foreign exchange contracts | 5 | Cost of sales | |||||||||||||||||||
4 | Total before tax | ||||||||||||||||||||
(2 | ) | Tax expense | |||||||||||||||||||
$ 2 | Net of tax | ||||||||||||||||||||
Total reclassification for the period | $(24 | ) | Total net of tax | ||||||||||||||||||
(a) | Amounts in parentheses indicate reductions to net income. | ||||||||||||||||||||
(b) | These AOCI components are included in the computation of net periodic benefit cost disclosed in Note 9. | ||||||||||||||||||||
Refer to Note 7 for additional information regarding hedging activity and Note 9 for additional information regarding the amortization of pension and other employee benefits items. |
INCOME_TAXES
INCOME TAXES | 3 Months Ended |
Mar. 31, 2015 | |
INCOME TAXES | 11. INCOME TAXES |
Effective tax rate | |
The company’s effective income tax rate for continuing operations was 20.8% and 22.4% in the first quarters of 2015 and 2014, respectively. The company’s effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate. In addition, the effective tax rate can be impacted each period by discrete factors and events. | |
The effective income tax rate decreased during the first quarter of 2015 compared to the first quarter of 2014 primarily as a result of a shift in the mix of earnings from higher tax countries to lower tax countries, which includes the impact of deductions of costs incurred related to the company’s planned spin-off of the biopharmaceuticals business. |
LEGAL_PROCEEDINGS
LEGAL PROCEEDINGS | 3 Months Ended |
Mar. 31, 2015 | |
LEGAL PROCEEDINGS | 12. LEGAL PROCEEDINGS |
Baxter is involved in product liability, patent, commercial, and other legal matters that arise in the normal course of the company’s business. The company records a liability when a loss is considered probable and the amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate, the minimum amount in the range is accrued. If a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. As of March 31, 2015, the company’s total recorded reserves with respect to legal matters were $64 million. | |
Baxter has established reserves for certain of the matters discussed below. The company is not able to estimate the amount or range of any loss for certain contingencies for which there is no reserve or additional loss for matters already reserved. While the liability of the company in connection with the claims cannot be estimated and although the resolution in any reporting period of one or more of these matters could have a significant impact on the company’s results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on the company’s consolidated financial position. While the company believes that it has valid defenses in these matters, litigation is inherently uncertain, excessive verdicts do occur, and the company may incur material judgments or enter into material settlements of claims. | |
In addition to the matters described below, the company remains subject to the risk of future administrative and legal actions. With respect to governmental and regulatory matters, these actions may lead to product recalls, injunctions, and other restrictions on the company’s operations and monetary sanctions, including significant civil or criminal penalties. With respect to intellectual property, the company may be exposed to significant litigation concerning the scope of the company’s and others’ rights. Such litigation could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially affect future results of operations. | |
General litigation | |
Baxter is a defendant in a number of suits alleging that certain of the company’s current and former executive officers and its board of directors failed to adequately oversee the operations of the company and issued materially false and misleading statements regarding the company’s plasma-based therapies business, the company’s remediation of its COLLEAGUE infusion pumps, its heparin product, and other quality matters. Plaintiffs allege these actions damaged the company and its shareholders by resulting in a decline in stock price in the second quarter of 2010, payment of excess compensation to the board of directors and certain of the company’s current and former executive officers, and other damage to the company. A consolidated derivative suit filed in the U.S.D.C. for the Northern District of Illinois was settled with the plaintiffs in February 2015, and as a result the two other derivative actions previously filed in state courts, one in Lake County, Illinois and one in the Delaware Chancery Court, were dismissed. Separate from these actions, a consolidated alleged class action is pending in the U.S.D.C. for the Northern District of Illinois against the company and certain of its current executive officers seeking to recover the lost value of investors’ stock and the parties are currently proceeding with discovery. In April 2013, the company filed its opposition to the plaintiff’s motion to certify a class action, which motion is pending. | |
Other | |
In May 2014, the company received a formal demand for information from the United States Attorney for the Western District of Pennsylvania for information related to alleged “off-label” sales of its pulmonary treatments. The Department of Justice informed the company on February 27, 2015 that its investigation is closed. | |
In the fourth quarter of 2012, the company received two investigative demands from the United States Attorney for the Western District of North Carolina for information regarding its quality and manufacturing practices and procedures at its North Cove facility. The company is fully cooperating with this investigation. |
SEGMENT_INFORMATION
SEGMENT INFORMATION | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
SEGMENT INFORMATION | 13. SEGMENT INFORMATION | ||||||||
Baxter’s two segments, BioScience and Medical Products, are strategic businesses that are managed separately because each business develops, manufactures and markets distinct products and services. Prior to 2015, the company’s biosurgery products and services were reported in the BioScience segment. In preparation of the planned spin-off of the biopharmaceuticals business, the company has realigned its biosurgery products and services to the Medical Products segment. Effective January 1, 2015, the company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation. | |||||||||
The segments and a description of their products and services are as follows: | |||||||||
The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions. Additionally, the BioScience business is investing in new disease areas, including oncology, as well as emerging technology platforms, including gene therapy and biosimilars. | |||||||||
The Medical Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. In addition, the Medical Products business provides products and services to treat end-stage renal disease, or irreversible kidney failure, along with other renal therapies, which business was enhanced through the 2013 acquisition of Gambro. The Medical Products business now offers a comprehensive portfolio to meet the needs of patients across the treatment continuum, including technologies and therapies for peritoneal dialysis (PD), in-center hemodialysis (HD), home HD (HHD), continuous renal replacement therapy (CRRT) and additional dialysis services. | |||||||||
The operating results of the Vaccines franchise, previously reported within the BioScience segment, have been reflected as discontinued operations for the three months ended March 31, 2015 and 2014. Refer to Note 1 for additional information regarding the presentation of the Vaccines franchise. | |||||||||
The company uses more than one measurement and multiple views of data to measure segment performance and to allocate resources to the segments. However, the dominant measurements are consistent with the company’s condensed consolidated financial statements and, accordingly, are reported on the same basis in this report. The company evaluates the performance of its segments and allocates resources to them primarily based on pre-tax income along with cash flows and overall economic returns. Intersegment sales are eliminated in consolidation. | |||||||||
Certain items are maintained at Corporate and are not allocated to a segment. They primarily include most of the company’s debt and cash and equivalents and related net interest expense, foreign exchange fluctuations (principally relating to intercompany receivables, payables and loans denominated in a foreign currency) and the majority of the foreign currency hedging activities, corporate headquarters costs, stock compensation expense, nonstrategic investments and related income and expense, certain employee benefit plan costs as well as certain nonrecurring gains, losses, and other charges (such as business optimization and asset impairment). With respect to depreciation and amortization and expenditures for long-lived assets, the difference between the segment totals and the consolidated totals principally relate to assets maintained at Corporate. Financial information for the company’s segments is as follows. | |||||||||
Three months ended | |||||||||
March 31, | |||||||||
(in millions) | 2015 | 2014 | |||||||
Net sales | |||||||||
BioScience | $ 1,361 | $ 1,329 | |||||||
Medical Products | 2,403 | 2,519 | |||||||
Total net sales | $ 3,764 | $ 3,848 | |||||||
Pre-tax income from continuing operations | |||||||||
BioScience | $ 436 | $ 484 | |||||||
Medical Products | 272 | 342 | |||||||
Total pre-tax income from continuing operations from segments | $ 708 | $ 826 | |||||||
March 31, | December 31, | ||||||||
(in millions) | 2015 | 2014 | |||||||
Total assets | |||||||||
BioScience | $ 9,379 | $ 9,312 | |||||||
Medical Products | 11,316 | 12,064 | |||||||
Other | 4,166 | 4,541 | |||||||
Total assets | $24,861 | $25,917 | |||||||
The following is a reconciliation of segment pre-tax income from continuing operations to income before income taxes from continuing operations per the condensed consolidated statements of income. | |||||||||
Three months ended | |||||||||
March 31, | |||||||||
(in millions) | 2015 | 2014 | |||||||
Total pre-tax income from continuing operations from segments | $708 | $826 | |||||||
Unallocated amounts | |||||||||
Stock compensation | (39 | ) | (31 | ) | |||||
Net interest expense | (30 | ) | (43 | ) | |||||
Business optimization items | 11 | (20 | ) | ||||||
Certain foreign currency fluctuations and hedging activities | 115 | 16 | |||||||
Other Corporate items | (235 | ) | (95 | ) | |||||
Income from continuing operations before income taxes | $530 | $653 | |||||||
BASIS_OF_PRESENTATION_Tables
BASIS OF PRESENTATION (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Summary of Operating Results Reflected as Discontinued Operations and Assets and Liabilities Classified as Held for Sale Associated with Franchise Vaccines | Following is a summary of the operating results of the Vaccines franchise, which have been reflected as discontinued operations for the three months ended March 31, 2015 and 2014. | ||||||||
Three months ended | |||||||||
March 31, | |||||||||
(in millions) | 2015 | 2014 | |||||||
Net sales | $ 1 | $103 | |||||||
Income before income taxes | 11 | 56 | |||||||
Income tax expense | 1 | 7 | |||||||
Net income | $10 | $ 49 | |||||||
SUPPLEMENTAL_FINANCIAL_INFORMA1
SUPPLEMENTAL FINANCIAL INFORMATION (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Net Interest Expense | Net interest expense | ||||||||
Three months ended | |||||||||
March 31, | |||||||||
(in millions) | 2015 | 2014 | |||||||
Interest expense, net of capitalized interest | $35 | $48 | |||||||
Interest income | (5 | ) | (5 | ) | |||||
Net interest expense | $30 | $43 | |||||||
Inventories | Inventories | ||||||||
March 31, | December 31, | ||||||||
(in millions) | 2015 | 2014 | |||||||
Raw materials | $ 859 | $ 910 | |||||||
Work in process | 1,107 | 1,126 | |||||||
Finished goods | 1,535 | 1,523 | |||||||
Inventories | $3,501 | $3,559 | |||||||
Property, Plant and Equipment, Net | Property, plant and equipment, net | ||||||||
March 31, | December 31, | ||||||||
(in millions) | 2015 | 2014 | |||||||
Property, plant and equipment, at cost | $14,366 | $14,808 | |||||||
Accumulated depreciation | (5,874 | ) | (6,110 | ) | |||||
Property, plant and equipment (PP&E), net | $ 8,492 | $ 8,698 | |||||||
EARNINGS_PER_SHARE_Tables
EARNINGS PER SHARE (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Reconciliation of Basic Shares to Diluted Shares | The following is a reconciliation of basic shares to diluted shares. | ||||||||
Three months ended | |||||||||
March 31, | |||||||||
(in millions) | 2015 | 2014 | |||||||
Basic shares | 543 | 542 | |||||||
Effect of dilutive securities | 5 | 6 | |||||||
Diluted shares | 548 | 548 | |||||||
ACQUISITIONS_AND_COLLABORATION1
ACQUISITIONS AND COLLABORATIONS (Tables) | 3 Months Ended | ||||
Mar. 31, 2015 | |||||
Summary of Fair Value of Consideration Transferred and Amounts Recognized for Assets Acquired and Liabilities Assumed | The following table summarizes the fair value of the consideration transferred and the recognized amounts of the assets acquired and liabilities assumed as of the acquisition date. | ||||
(in millions) | |||||
Consideration transferred | |||||
Cash, net of cash acquired | $228 | ||||
Fair value of consideration transferred | $228 | ||||
Assets acquired and liabilities assumed | |||||
Deferred tax asset | $ 17 | ||||
In-process research and development (IPR&D) | 179 | ||||
Other assets, net | 1 | ||||
Deferred tax liability | (52 | ) | |||
Total identifiable net assets | 145 | ||||
Goodwill | 83 | ||||
Total assets acquired and liabilities assumed | $228 | ||||
GOODWILL_AND_OTHER_INTANGIBLE_1
GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables) | 3 Months Ended | ||||||||||||||||
Mar. 31, 2015 | |||||||||||||||||
Goodwill | The following is a reconciliation of goodwill by business segment. | ||||||||||||||||
(in millions) | BioScience | Medical Products | Total | ||||||||||||||
Balance as of December 31, 2014 | $ 947 | $2,927 | $3,874 | ||||||||||||||
Additions | 83 | — | 83 | ||||||||||||||
Currency translation and other adjustments | (27 | ) | (236 | ) | (263 | ) | |||||||||||
Balance as of March 31, 2015 | $1,003 | $2,691 | $3,694 | ||||||||||||||
Other Intangible Assets, Net | The following is a summary of the company’s other intangible assets. | ||||||||||||||||
(in millions) | Developed technology, | Other amortized | Indefinite-lived | Total | |||||||||||||
including patents | intangible assets | intangible assets | |||||||||||||||
March 31, 2015 | |||||||||||||||||
Gross other intangible assets | $2,171 | $414 | $406 | $2,991 | |||||||||||||
Accumulated amortization | (778 | ) | (145 | ) | — | (923 | ) | ||||||||||
Other intangible assets, net | $1,393 | $269 | $406 | $2,068 | |||||||||||||
December 31, 2014 | |||||||||||||||||
Gross other intangible assets | $2,278 | $443 | $272 | $2,993 | |||||||||||||
Accumulated amortization | (769 | ) | (145 | ) | — | (914 | ) | ||||||||||
Other intangible assets, net | $1,509 | $298 | $272 | $2,079 | |||||||||||||
Indefinite-lived intangible assets | The following is a summary of the company’s other intangible assets. | ||||||||||||||||
(in millions) | Developed technology, | Other amortized | Indefinite-lived | Total | |||||||||||||
including patents | intangible assets | intangible assets | |||||||||||||||
March 31, 2015 | |||||||||||||||||
Gross other intangible assets | $2,171 | $414 | $406 | $2,991 | |||||||||||||
Accumulated amortization | (778 | ) | (145 | ) | — | (923 | ) | ||||||||||
Other intangible assets, net | $1,393 | $269 | $406 | $2,068 | |||||||||||||
December 31, 2014 | |||||||||||||||||
Gross other intangible assets | $2,278 | $443 | $272 | $2,993 | |||||||||||||
Accumulated amortization | (769 | ) | (145 | ) | — | (914 | ) | ||||||||||
Other intangible assets, net | $1,509 | $298 | $272 | $2,079 | |||||||||||||
INFUSION_PUMP_AND_BUSINESS_OPT1
INFUSION PUMP AND BUSINESS OPTIMIZATION CHARGES (Tables) | 3 Months Ended | ||||
Mar. 31, 2015 | |||||
Business Optimization Initiatives | The following table summarizes cash activity in the reserves related to the company’s business optimization initiatives. | ||||
(in millions) | |||||
Reserves as of December 31, 2014 | $ | 169 | |||
Charges | 16 | ||||
Reserve adjustments | (29 | ) | |||
Utilization | (20 | ) | |||
CTA | (9 | ) | |||
Reserves as of March 31, 2015 | $ | 127 | |||
DEBT_FINANCIAL_INSTRUMENTS_AND1
DEBT, FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables) | 3 Months Ended | ||||||||||||||||||||
Mar. 31, 2015 | |||||||||||||||||||||
Summary of Activity Relating to Securitization Arrangement | The following is a summary of the activity relating to the company’s securitization arrangement in Japan. | ||||||||||||||||||||
Three months ended | |||||||||||||||||||||
March 31, | |||||||||||||||||||||
(in millions) | 2015 | 2014 | |||||||||||||||||||
Sold receivables at beginning of period | $104 | $114 | |||||||||||||||||||
Proceeds from sales of receivables | 113 | 123 | |||||||||||||||||||
Cash collections (remitted to the owners of the receivables) | (120 | ) | (129 | ) | |||||||||||||||||
Effect of currency exchange rate changes | (1 | ) | 1 | ||||||||||||||||||
Sold receivables at end of period | $ 96 | $109 | |||||||||||||||||||
Summary of Gains and Losses on Derivative Instruments | The following table summarizes the income statement locations and gains and losses on the company’s derivative instruments for the three months ended March 31, 2015 and 2014. | ||||||||||||||||||||
Gain (loss) recognized in OCI | Location of gain (loss) | Gain (loss) reclassified from AOCI | |||||||||||||||||||
in income statement | into income | ||||||||||||||||||||
(in millions) | 2015 | 2014 | 2015 | 2014 | |||||||||||||||||
Cash flow hedges | |||||||||||||||||||||
Interest rate contracts | $(55 | ) | $ — | Net interest expense | $— | $(1 | ) | ||||||||||||||
Foreign exchange contracts | (1 | ) | (1 | ) | Net sales | — | — | ||||||||||||||
Foreign exchange contracts | 64 | (11 | ) | Cost of sales | 25 | 5 | |||||||||||||||
Total | $ 8 | $(12 | ) | $25 | $ 4 | ||||||||||||||||
Gain (loss) recognized in income | |||||||||||||||||||||
(in millions) | Location of gain (loss) in income statement | 2015 | 2014 | ||||||||||||||||||
Fair value hedges | |||||||||||||||||||||
Interest rate contracts | Net interest expense | $47 | $14 | ||||||||||||||||||
Undesignated derivative instruments | |||||||||||||||||||||
Foreign exchange contracts | Other income, net | $ (8 | ) | $12 | |||||||||||||||||
Classification and Fair Value Amounts of Derivative Instruments | The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of March 31, 2015. | ||||||||||||||||||||
Derivatives in asset positions | Derivatives in liability positions | ||||||||||||||||||||
(in millions) | Balance sheet location | Fair value | Balance sheet location | Fair value | |||||||||||||||||
Derivative instruments designated as hedges | |||||||||||||||||||||
Interest rate contracts | Prepaid expenses and other | $ — | Accounts payable and | $56 | |||||||||||||||||
accrued liabilities | |||||||||||||||||||||
Interest rate contracts | Other long-term assets | 136 | Other long-term liabilities | — | |||||||||||||||||
Foreign exchange contracts | Prepaid expenses and other | 79 | Accounts payable | — | |||||||||||||||||
and accrued liabilities | |||||||||||||||||||||
Total derivative instruments designated as hedges | $215 | $56 | |||||||||||||||||||
Undesignated derivative instruments | |||||||||||||||||||||
Foreign exchange contracts | Prepaid expenses and other | $ — | Accounts payable | $ 2 | |||||||||||||||||
and accrued liabilities | |||||||||||||||||||||
Total derivative instruments | $215 | $58 | |||||||||||||||||||
The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2014. | |||||||||||||||||||||
Derivatives in asset positions | Derivatives in liability positions | ||||||||||||||||||||
(in millions) | Balance sheet location | Fair value | Balance sheet location | Fair value | |||||||||||||||||
Derivative instruments designated as hedges | |||||||||||||||||||||
Interest rate contracts | Prepaid expenses and other | $ 1 | Accounts payable | $ 2 | |||||||||||||||||
and accrued liabilities | |||||||||||||||||||||
Interest rate contracts | Other long-term assets | 89 | Other long-term liabilities | — | |||||||||||||||||
Foreign exchange contracts | Prepaid expenses and other | 51 | Accounts payable | — | |||||||||||||||||
and accrued liabilities | |||||||||||||||||||||
Total derivative instruments designated as hedges | $141 | $ 2 | |||||||||||||||||||
Undesignated derivative instruments | |||||||||||||||||||||
Foreign exchange contracts | Prepaid expenses and other | $ — | Accounts payable | $23 | |||||||||||||||||
and accrued liabilities | |||||||||||||||||||||
Total derivative instruments | $141 | $25 | |||||||||||||||||||
Derivative Positions Presented on Net Basis | The following table provides information on the company’s derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty. | ||||||||||||||||||||
March 31, 2015 | December 31, 2014 | ||||||||||||||||||||
(in millions) | Asset | Liability | Asset | Liability | |||||||||||||||||
Gross amounts recognized in the consolidated balance sheet | $215 | $58 | $141 | $25 | |||||||||||||||||
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet | (58 | ) | (58 | ) | (22 | ) | (22 | ) | |||||||||||||
Total | $157 | $— | $119 | $ 3 | |||||||||||||||||
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis | The following tables summarize the bases used to measure financial assets and liabilities that are carried at fair value on a recurring basis in the condensed consolidated balance sheets. | ||||||||||||||||||||
Basis of fair value measurement | |||||||||||||||||||||
(in millions) | Balance as of | Quoted prices in | Significant other | Significant | |||||||||||||||||
active markets for | observable inputs | unobservable | |||||||||||||||||||
March 31, 2015 | identical assets | ||||||||||||||||||||
(Level 2) | inputs | ||||||||||||||||||||
(Level 1) | |||||||||||||||||||||
(Level 3) | |||||||||||||||||||||
Assets | |||||||||||||||||||||
Foreign currency hedges | $ 79 | $ — | $ 79 | $ — | |||||||||||||||||
Interest rate hedges | 136 | — | 136 | — | |||||||||||||||||
Available-for-sale securities | |||||||||||||||||||||
Equity securities | 120 | 120 | — | — | |||||||||||||||||
Foreign government debt securities | 15 | — | 15 | — | |||||||||||||||||
Total assets | $350 | $120 | $230 | $ — | |||||||||||||||||
Liabilities | |||||||||||||||||||||
Foreign currency hedges | $ 2 | $ — | $ 2 | $ — | |||||||||||||||||
Interest rate hedges | 56 | — | 56 | — | |||||||||||||||||
Contingent payments related to acquisitions | 541 | — | — | 541 | |||||||||||||||||
Total liabilities | $599 | $ — | $ 58 | $541 | |||||||||||||||||
Basis of fair value measurement | |||||||||||||||||||||
(in millions) | Balance as of | Quoted prices in | Significant other | Significant | |||||||||||||||||
active markets for | observable inputs | unobservable | |||||||||||||||||||
December 31, 2014 | identical assets | ||||||||||||||||||||
(Level 2) | inputs | ||||||||||||||||||||
(Level 1) | |||||||||||||||||||||
(Level 3) | |||||||||||||||||||||
Assets | |||||||||||||||||||||
Foreign currency hedges | $ 51 | $ — | $ 51 | $ — | |||||||||||||||||
Interest rate hedges | 90 | — | 90 | — | |||||||||||||||||
Available-for-sale securities | |||||||||||||||||||||
Equity securities | 105 | 105 | — | — | |||||||||||||||||
Foreign government debt securities | 18 | — | 18 | — | |||||||||||||||||
Total assets | $264 | $105 | $159 | $ — | |||||||||||||||||
Liabilities | |||||||||||||||||||||
Foreign currency hedges | $ 23 | $ — | $ 23 | $ — | |||||||||||||||||
Interest rate hedges | 2 | — | 2 | — | |||||||||||||||||
Contingent payments related to acquisitions | 569 | — | — | 569 | |||||||||||||||||
Total liabilities | $594 | $ — | $ 25 | $569 | |||||||||||||||||
Book Values and Fair Values of Financial Instruments | For these financial instruments, the following table provides the values recognized in the condensed consolidated balance sheets and the approximate fair values as of March 31, 2015 and December 31, 2014. | ||||||||||||||||||||
Book values | Approximate fair values | ||||||||||||||||||||
(in millions) | 2015 | 2014 | 2015 | 2014 | |||||||||||||||||
Assets | |||||||||||||||||||||
Investments | $ 59 | $ 54 | $ 59 | $ 52 | |||||||||||||||||
Liabilities | |||||||||||||||||||||
Short-term debt | 2,151 | 913 | 2,151 | 913 | |||||||||||||||||
Current maturities of long-term debt and lease obligations | 174 | 786 | 174 | 791 | |||||||||||||||||
Long-term debt and lease obligations | 7,680 | 7,606 | 8,235 | 8,192 | |||||||||||||||||
Long-term litigation liabilities | 48 | 53 | 47 | 52 | |||||||||||||||||
Summarization of Bases Used to Measure Fair Value of Financial Instruments | The following tables summarize the bases used to measure the approximate fair value of the financial instruments as of March 31, 2015 and December 31, 2014. | ||||||||||||||||||||
Basis of fair value measurement | |||||||||||||||||||||
(in millions) | Fair value as of | Quoted prices in | Significant other | Significant | |||||||||||||||||
active markets for | observable inputs | unobservable | |||||||||||||||||||
March 31, 2015 | identical assets | ||||||||||||||||||||
(Level 2) | inputs | ||||||||||||||||||||
(Level 1) | |||||||||||||||||||||
(Level 3) | |||||||||||||||||||||
Assets | |||||||||||||||||||||
Investments | $ 59 | $— | $ 10 | $49 | |||||||||||||||||
Total assets | $ 59 | $— | $10 | $49 | |||||||||||||||||
Liabilities | |||||||||||||||||||||
Short-term debt | $ 2,151 | $— | $ 2,151 | $— | |||||||||||||||||
Current maturities of long-term debt and lease obligations | 174 | — | 174 | — | |||||||||||||||||
Long-term debt and lease obligations | 8,235 | — | 8,235 | — | |||||||||||||||||
Long-term litigation liabilities | 47 | — | — | 47 | |||||||||||||||||
Total liabilities | $10,607 | $— | $10,560 | $47 | |||||||||||||||||
Basis of fair value measurement | |||||||||||||||||||||
(in millions) | Fair value as of | Quoted prices in | Significant other | Significant | |||||||||||||||||
active markets for | observable inputs | unobservable | |||||||||||||||||||
December 31, 2014 | identical assets | ||||||||||||||||||||
(Level 2) | inputs | ||||||||||||||||||||
(Level 1) | |||||||||||||||||||||
(Level 3) | |||||||||||||||||||||
Assets | |||||||||||||||||||||
Investments | $ 52 | $— | $ 8 | $44 | |||||||||||||||||
Total assets | $ 52 | $— | $ 8 | $44 | |||||||||||||||||
Liabilities | |||||||||||||||||||||
Short-term debt | $ 913 | $— | $ 913 | $— | |||||||||||||||||
Current maturities of long-term debt and lease obligations | 791 | — | 791 | — | |||||||||||||||||
Long-term debt and lease obligations | 8,192 | — | 8,192 | — | |||||||||||||||||
Long-term litigation liabilities | 52 | — | — | 52 | |||||||||||||||||
Total liabilities | $9,948 | $— | $9,896 | $52 | |||||||||||||||||
STOCK_COMPENSATION_Tables
STOCK COMPENSATION (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Stock Options Fair Value Assumptions | The weighted-average Black-Scholes assumptions used in estimating the fair value of stock options granted during the period, along with the weighted-average grant-date fair values, were as follows. | ||||||||
Three months ended | |||||||||
March 31, | |||||||||
2015 | 2014 | ||||||||
Expected volatility | 20% | 24% | |||||||
Expected life (in years) | 5.5 | 5.5 | |||||||
Risk-free interest rate | 1.70% | 1.70% | |||||||
Dividend yield | 3.00% | 2.80% | |||||||
Fair value per stock option | $9 | $12 |
RETIREMENT_AND_OTHER_BENEFIT_P1
RETIREMENT AND OTHER BENEFIT PROGRAMS (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Net Periodic Benefit Cost Relating to Pension and Other Postemployement Benefit | The following is a summary of net periodic benefit cost relating to the company’s pension and other postemployment benefit (OPEB) plans. | ||||||||
Three months ended | |||||||||
March 31, | |||||||||
(in millions) | 2015 | 2014 | |||||||
Pension benefits | |||||||||
Service cost | $37 | $33 | |||||||
Interest cost | 55 | 60 | |||||||
Expected return on plan assets | (67 | ) | (66 | ) | |||||
Amortization of net losses and other deferred amounts | 51 | 36 | |||||||
Net periodic pension benefit cost | $76 | $63 | |||||||
OPEB | |||||||||
Service cost | $ 1 | $ 1 | |||||||
Interest cost | 6 | 7 | |||||||
Amortization of net loss and prior service credit | (1 | ) | — | ||||||
Net periodic OPEB cost | $ 6 | $ 8 | |||||||
SHAREHOLDERS_EQUITY_Tables
SHAREHOLDERS' EQUITY (Tables) | 3 Months Ended | ||||||||||||||||||||
Mar. 31, 2015 | |||||||||||||||||||||
Summary of Changes in AOCI by Component | The following is a net-of-tax summary of the changes in AOCI by component for the three months ended March 31, 2015 and 2014. | ||||||||||||||||||||
(in millions) | CTA | Pension and | Hedging | Other | Total | ||||||||||||||||
other employee | activities | ||||||||||||||||||||
benefits | |||||||||||||||||||||
Gains (losses) | |||||||||||||||||||||
Balance as of December 31, 2014 | $(2,323 | ) | $(1,427 | ) | $34 | $66 | $(3,650 | ) | |||||||||||||
Other comprehensive income before reclassifications | (1,138 | ) | 33 | 6 | 14 | (1,085 | ) | ||||||||||||||
Amounts reclassified from AOCI (a) | — | 35 | (16 | ) | 7 | 26 | |||||||||||||||
Net other comprehensive (loss) income | (1,138 | ) | 68 | (10 | ) | 21 | (1,059 | ) | |||||||||||||
Balance as of March 31, 2015 | $(3,461 | ) | $(1,359 | ) | $24 | $87 | $(4,709 | ) | |||||||||||||
(in millions) | CTA | Pension and | Hedging | Other | Total | ||||||||||||||||
other employee | activities | ||||||||||||||||||||
benefits | |||||||||||||||||||||
Gains (losses) | |||||||||||||||||||||
Balance as of December 31, 2013 | $ (991 | ) | $(1,027 | ) | $10 | $32 | $(1,976 | ) | |||||||||||||
Other comprehensive income before reclassifications | 6 | (3 | ) | (8 | ) | 11 | 6 | ||||||||||||||
Amounts reclassified from AOCI (a) | — | 26 | (2 | ) | — | 24 | |||||||||||||||
Net other comprehensive income (loss) | 6 | 23 | (10 | ) | 11 | 30 | |||||||||||||||
Balance as of March 31, 2014 | $ (985 | ) | $(1,004 | ) | $— | $43 | $(1,946 | ) | |||||||||||||
(a) | See table below for details about these reclassifications. | ||||||||||||||||||||
Summary of Reclassification from AOCI to Net Income | The following is a summary of the amounts reclassified from AOCI to net income during the three months ended March 31, 2015 and 2014. | ||||||||||||||||||||
Amount | |||||||||||||||||||||
reclassified | |||||||||||||||||||||
from AOCI (a) | |||||||||||||||||||||
(in millions) | 2015 | Location of impact in income statement | |||||||||||||||||||
Amortization of pension and other employee benefits items | |||||||||||||||||||||
Actuarial losses and other | $(50 | )(b) | |||||||||||||||||||
(50 | ) | Total before tax | |||||||||||||||||||
15 | Tax benefit | ||||||||||||||||||||
$(35 | ) | Net of tax | |||||||||||||||||||
Gains (losses) on hedging activities | |||||||||||||||||||||
Interest rate contracts | $ — | Net interest expense | |||||||||||||||||||
Foreign exchange contracts | — | Net sales | |||||||||||||||||||
Foreign exchange contracts | 25 | Cost of sales | |||||||||||||||||||
25 | Total before tax | ||||||||||||||||||||
(9 | ) | Tax expense | |||||||||||||||||||
$ 16 | Net of tax | ||||||||||||||||||||
Other | |||||||||||||||||||||
Other-than-temporary impairment of available-for-sale equity securities | $ (9 | ) | Other income, net | ||||||||||||||||||
(9 | ) | Total before tax | |||||||||||||||||||
2 | Tax benefit | ||||||||||||||||||||
$ (7 | ) | Net of tax | |||||||||||||||||||
Total reclassification for the period | $(26 | ) | Total net of tax | ||||||||||||||||||
Amount | |||||||||||||||||||||
reclassified | |||||||||||||||||||||
from AOCI (a) | |||||||||||||||||||||
(in millions) | 2014 | Location of impact in income statement | |||||||||||||||||||
Amortization of pension and other employee benefits items | |||||||||||||||||||||
Actuarial losses and other | $(36 | )(b) | |||||||||||||||||||
(36 | ) | Total before tax | |||||||||||||||||||
10 | Tax benefit | ||||||||||||||||||||
$(26 | ) | Net of tax | |||||||||||||||||||
Gains on hedging activities | |||||||||||||||||||||
Interest rate contracts | $ (1 | ) | Net interest expense | ||||||||||||||||||
Foreign exchange contracts | — | Net sales | |||||||||||||||||||
Foreign exchange contracts | 5 | Cost of sales | |||||||||||||||||||
4 | Total before tax | ||||||||||||||||||||
(2 | ) | Tax expense | |||||||||||||||||||
$ 2 | Net of tax | ||||||||||||||||||||
Total reclassification for the period | $(24 | ) | Total net of tax | ||||||||||||||||||
(a) | Amounts in parentheses indicate reductions to net income. | ||||||||||||||||||||
(b) | These AOCI components are included in the computation of net periodic benefit cost disclosed in Note 9. |
SEGMENT_INFORMATION_Tables
SEGMENT INFORMATION (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Segment Information | Financial information for the company’s segments is as follows. | ||||||||
Three months ended | |||||||||
March 31, | |||||||||
(in millions) | 2015 | 2014 | |||||||
Net sales | |||||||||
BioScience | $ 1,361 | $ 1,329 | |||||||
Medical Products | 2,403 | 2,519 | |||||||
Total net sales | $ 3,764 | $ 3,848 | |||||||
Pre-tax income from continuing operations | |||||||||
BioScience | $ 436 | $ 484 | |||||||
Medical Products | 272 | 342 | |||||||
Total pre-tax income from continuing operations from segments | $ 708 | $ 826 | |||||||
March 31, | December 31, | ||||||||
(in millions) | 2015 | 2014 | |||||||
Total assets | |||||||||
BioScience | $ 9,379 | $ 9,312 | |||||||
Medical Products | 11,316 | 12,064 | |||||||
Other | 4,166 | 4,541 | |||||||
Total assets | $24,861 | $25,917 | |||||||
Pre-Tax Income from Continuing Operations Reconciliation | The following is a reconciliation of segment pre-tax income from continuing operations to income before income taxes from continuing operations per the condensed consolidated statements of income. | ||||||||
Three months ended | |||||||||
March 31, | |||||||||
(in millions) | 2015 | 2014 | |||||||
Total pre-tax income from continuing operations from segments | $708 | $826 | |||||||
Unallocated amounts | |||||||||
Stock compensation | (39 | ) | (31 | ) | |||||
Net interest expense | (30 | ) | (43 | ) | |||||
Business optimization items | 11 | (20 | ) | ||||||
Certain foreign currency fluctuations and hedging activities | 115 | 16 | |||||||
Other Corporate items | (235 | ) | (95 | ) | |||||
Income from continuing operations before income taxes | $530 | $653 | |||||||
Basis_of_Presentation_Addition
Basis of Presentation- Additional Information (Detail) (Vaccines, USD $) | 3 Months Ended |
In Millions, unless otherwise specified | Mar. 31, 2015 |
Vaccines | |
Disclosure Basis Of Presentation Details [Line Items] | |
After-tax gain from divestiture of commercial vaccines business | $9 |
Summary_of_Operating_Results_R
Summary of Operating Results Reflected as Discontinued Operations (Detail) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||
Net income | $10 | $49 |
Vaccines Franchise | ||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||
Net sales | 1 | 103 |
Income before income taxes | 11 | 56 |
Income tax expense | 1 | 7 |
Net income | $10 | $49 |
Net_Interest_Expense_Detail
Net Interest Expense (Detail) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Interest Income Expense Net | ||
Interest expense, net of capitalized interest | $35 | $48 |
Interest income | -5 | -5 |
Net interest expense | $30 | $43 |
Inventories_Detail
Inventories (Detail) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Millions, unless otherwise specified | ||
Inventory | ||
Raw materials | $859 | $910 |
Work in process | 1,107 | 1,126 |
Finished goods | 1,535 | 1,523 |
Inventories | $3,501 | $3,559 |
Property_Plant_and_Equipment_N
Property, Plant and Equipment ,Net (Detail) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Millions, unless otherwise specified | ||
Property, Plant and Equipment, Net | ||
Property, plant and equipment, at cost | $14,366 | $14,808 |
Accumulated depreciation | -5,874 | -6,110 |
Property, plant and equipment (PP&E), net | $8,492 | $8,698 |
Reconciliation_of_Basic_Shares
Reconciliation of Basic Shares to Diluted Shares (Detail) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Reconciliation of Basic Shares to Diluted Shares | ||
Basic shares | 543 | 542 |
Effect of dilutive securities | 5 | 6 |
Diluted shares | 548 | 548 |
Earnings_Per_Share_Additional_
Earnings Per Share - Additional Information (Detail) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-dilutive securities excluded from computation of EPS | 9 | 8 |
Summary_of_Fair_Value_of_Consi
Summary of Fair Value of Consideration Transferred and Amounts Recognized for Assets Acquired and Liabilities Assumed (Detail) (USD $) | 3 Months Ended | ||
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 | Dec. 31, 2014 |
Consideration transferred | |||
Cash, net of cash acquired | $235 | $59 | |
Assets acquired and liabilities assumed | |||
Goodwill | 3,694 | 3,874 | |
SuppreMol GmbH | |||
Consideration transferred | |||
Cash, net of cash acquired | 228 | ||
Fair value of consideration transferred | 228 | ||
Assets acquired and liabilities assumed | |||
Deferred tax asset | 17 | ||
In-process research and development (IPR&D) | 179 | ||
Other assets, net | 1 | ||
Deferred tax liability | -52 | ||
Total identifiable net assets | 145 | ||
Goodwill | 83 | ||
Total assets acquired and liabilities assumed | $228 |
Recovered_Sheet1
Acquisitions and Collaborations - Additional Information (Detail) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Acquisitions And Collaborations [Line Items] | ||
Research and development charges | $300 | $309 |
SuppreMol GmbH | ||
Acquisitions And Collaborations [Line Items] | ||
In-process research and development (IPR&D) | 179 | |
IPR&D completion term | 5 years | |
SuppreMol GmbH | In-process research and development (IPR&D) | ||
Acquisitions And Collaborations [Line Items] | ||
Cash flow projections discount rate | 20.00% | |
SuppreMol GmbH | Minimum | In-process research and development (IPR&D) | ||
Acquisitions And Collaborations [Line Items] | ||
Research and development charges | 400 | |
Coherus Biosciences, Inc. | ||
Acquisitions And Collaborations [Line Items] | ||
Research and development charges | $25 |
Goodwill_Detail
Goodwill (Detail) (USD $) | 3 Months Ended |
In Millions, unless otherwise specified | Mar. 31, 2015 |
Goodwill [Line Items] | |
Goodwill, beginning balance | $3,874 |
Additions | 83 |
Currency translation and other adjustments | -263 |
Goodwill, ending balance | 3,694 |
BioScience | |
Goodwill [Line Items] | |
Goodwill, beginning balance | 947 |
Additions | 83 |
Currency translation and other adjustments | -27 |
Goodwill, ending balance | 1,003 |
Medical Products | |
Goodwill [Line Items] | |
Goodwill, beginning balance | 2,927 |
Currency translation and other adjustments | -236 |
Goodwill, ending balance | $2,691 |
Recovered_Sheet2
Goodwill and Other Intangible Assets, Net - Additional Information (Detail) (USD $) | 3 Months Ended | |
Mar. 31, 2015 | Mar. 31, 2014 | |
Goodwill And Other Intangible Asset [Line Items] | ||
Accumulated goodwill impairment losses | $0 | |
Amortization expense | 48,000,000 | 43,000,000 |
Anticipated annual amortization expense of other intangible assets for 2015 | 183,000,000 | |
Anticipated annual amortization expense of other intangible assets for 2016 | 181,000,000 | |
Anticipated annual amortization expense of other intangible assets for 2017 | 166,000,000 | |
Anticipated annual amortization expense of other intangible assets for 2018 | 161,000,000 | |
Anticipated annual amortization expense of other intangible assets for 2019 | 148,000,000 | |
Anticipated annual amortization expense of other intangible assets for 2020 | $146,000,000 |
Other_Intangible_Assets_Net_De
Other Intangible Assets, Net (Detail) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Millions, unless otherwise specified | ||
Intangible Asset Excluding Goodwill [Line Items] | ||
Gross other intangible assets | $2,991 | $2,993 |
Accumulated amortization | -923 | -914 |
Other intangible assets, net | 2,068 | 2,079 |
Developed technology, including patents | ||
Intangible Asset Excluding Goodwill [Line Items] | ||
Gross other intangible assets | 2,171 | 2,278 |
Accumulated amortization | -778 | -769 |
Other intangible assets, net | 1,393 | 1,509 |
Other Intangible Assets | ||
Intangible Asset Excluding Goodwill [Line Items] | ||
Gross other intangible assets | 414 | 443 |
Accumulated amortization | -145 | -145 |
Other intangible assets, net | 269 | 298 |
Indefinite Lived Intangible Assets | ||
Intangible Asset Excluding Goodwill [Line Items] | ||
Gross other intangible assets | 406 | 272 |
Accumulated amortization | 0 | 0 |
Other intangible assets, net | $406 | $272 |
Recovered_Sheet3
Infusion Pump and Business Optimization Charges - Additional Information (Detail) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Business Optimization Initiatives | ||
Reserve adjustments | ($29) | |
Costs associated with optimizing the cost structure | 16 | |
Discontinued Operations | ||
Business Optimization Initiatives | ||
Costs associated with optimizing the cost structure | 8 | |
Cost of Sales | ||
Business Optimization Initiatives | ||
Costs associated with optimizing the cost structure | -7 | 4 |
Marketing and Administrative Expenses | ||
Business Optimization Initiatives | ||
Costs associated with optimizing the cost structure | 2 | 10 |
Research and Development Expense | ||
Business Optimization Initiatives | ||
Costs associated with optimizing the cost structure | -6 | 6 |
Severance and employee-related costs | ||
Business Optimization Initiatives | ||
Costs associated with optimizing the cost structure | $18 | $28 |
Business_Optimization_Initiati
Business Optimization Initiatives (Detail) (USD $) | 3 Months Ended |
In Millions, unless otherwise specified | Mar. 31, 2015 |
Business Optimization Initiatives | |
Reserves, beginning balance | $169 |
Charges | 16 |
Reserve adjustments | -29 |
Utilization | -20 |
CTA | -9 |
Reserves, ending balance | $127 |
Summary_of_Activity_Relating_t
Summary of Activity Relating to Securitization Arrangement (Detail) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Accounts Receivable Securitization [Line Items] | ||
Sold receivables at beginning of period | $104 | $114 |
Proceeds from sales of receivables | 113 | 123 |
Cash collections (remitted to the owners of the receivables) | -120 | -129 |
Effect of currency exchange rate changes | -1 | 1 |
Sold receivables at end of period | $96 | $109 |
Recovered_Sheet4
Debt, Financial Instruments and Fair Value Measurements - Additional Information (Detail) (USD $) | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2015 | Mar. 31, 2014 | Dec. 31, 2014 | Dec. 31, 2013 | |
Debt and Financial Instruments [Line Items] | ||||
Borrowing | $0 | |||
Commercial paper outstanding | 1,200,000,000 | 875,000,000 | ||
Maximum length of time hedge in cash flow hedge | 12 months | |||
Losses on hedged item in fair value hedge | 47,000,000 | 14,000,000 | ||
Deferred, net after-tax gains on derivative instruments | 52,000,000 | |||
Cash and equivalents | 2,530,000,000 | 2,049,000,000 | 2,925,000,000 | 2,733,000,000 |
Weighted average probability | 26.00% | |||
Available for sale equity securities amortized cost basis | 63,000,000 | 79,000,000 | ||
Available for sale equity securities fair value | 120,000,000 | 105,000,000 | ||
Unfunded commitment payments | 85,000,000 | 38,000,000 | ||
Equity income recognized from equity method investments | 44,000,000 | |||
Countries With Liquidity Issues | ||||
Debt and Financial Instruments [Line Items] | ||||
Total accounts receivable from certain countries with liquidity issues | 328,000,000 | |||
Equity Securities | ||||
Debt and Financial Instruments [Line Items] | ||||
Available for sale equity securities net unrealized gain (loss) | 57,000,000 | 26,000,000 | ||
Available for sale equity securities cumulative unrealized losses | 1,000,000 | 9,000,000 | ||
Available for sale equity securities cumulative unrealized gain | 58,000,000 | 35,000,000 | ||
Available for sale equity securities other-than-temporary impairment charges | 9,000,000 | |||
Fair Value, Inputs, Level 2 | ||||
Debt and Financial Instruments [Line Items] | ||||
Money market funds, at carrying value | 196,000,000 | 989,000,000 | ||
Domestic Line of Credit | ||||
Debt and Financial Instruments [Line Items] | ||||
Borrowing | 900,000,000 | |||
Interest rate | 1.27% | |||
Line of Credit Facility Amount Outstanding | 900,000,000 | |||
Dedesignated As Hedging Instrument | ||||
Debt and Financial Instruments [Line Items] | ||||
Derivative notional amount | 0 | 0 | ||
Terminated Fair Value Hedge | ||||
Debt and Financial Instruments [Line Items] | ||||
Derivative notional amount | 0 | 0 | ||
Not Designated as Hedging Instrument | ||||
Debt and Financial Instruments [Line Items] | ||||
Derivative notional amount | 459,000,000 | 434,000,000 | ||
Foreign exchange contract | ||||
Debt and Financial Instruments [Line Items] | ||||
Derivative notional amount | 703,000,000 | 917,000,000 | ||
Interest rate contract | ||||
Debt and Financial Instruments [Line Items] | ||||
Derivative notional amount | 1,800,000,000 | 550,000,000 | ||
Interest rate contract | Fair value hedges | ||||
Debt and Financial Instruments [Line Items] | ||||
Derivative notional amount | $2,900,000,000 | $2,900,000,000 | ||
Commercial Paper | ||||
Debt and Financial Instruments [Line Items] | ||||
Debt instrument, weighted average interest rate | 0.66% | 0.46% |
Summary_of_Gains_and_Losses_on
Summary of Gains and Losses on Derivative Instruments (Detail) (USD $) | 3 Months Ended | |||
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Gains (losses) on hedging activities reclassified from AOCI to net income, before tax | $25 | [1] | $4 | [1] |
Other (income) expense, net | Not Designated as Hedging Instrument | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Gain (loss) recognized in income, undesignated derivative instruments | -8 | 12 | ||
Interest rate contract | Interest Expense | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Gains (losses) on hedging activities reclassified from AOCI to net income, before tax | -1 | [1] | ||
Cash Flow Hedges | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Gain (loss) recognized in OCI | 8 | -12 | ||
Gains (losses) on hedging activities reclassified from AOCI to net income, before tax | 25 | 4 | ||
Cash Flow Hedges | Interest rate contract | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Gain (loss) recognized in OCI | -55 | |||
Cash Flow Hedges | Interest rate contract | Interest Expense | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Gains (losses) on hedging activities reclassified from AOCI to net income, before tax | -1 | |||
Cash Flow Hedges | Foreign Exchange Contracts One | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Gain (loss) recognized in OCI | -1 | -1 | ||
Cash Flow Hedges | Foreign Exchange Contracts Two | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Gain (loss) recognized in OCI | 64 | -11 | ||
Cash Flow Hedges | Foreign Exchange Contracts Two | Cost of Sales | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Gains (losses) on hedging activities reclassified from AOCI to net income, before tax | 25 | 5 | ||
Fair value hedges | Interest Expense | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Gain (loss) recognized in income, fair value hedges | $47 | $14 | ||
[1] | Amounts in parentheses indicate reductions to net income. |
Classification_and_Fair_Value_
Classification and Fair Value Amounts of Derivative Instruments (Detail) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Millions, unless otherwise specified | ||
Derivatives, Fair Value [Line Items] | ||
Derivative asset, fair value | $215 | $141 |
Derivative liability, fair value | 58 | 25 |
Designated as Hedging Instrument | ||
Derivatives, Fair Value [Line Items] | ||
Derivative asset, fair value | 215 | 141 |
Derivative liability, fair value | 56 | 2 |
Designated as Hedging Instrument | Interest rate contract | Accounts Payable And Accrued Liabilities | ||
Derivatives, Fair Value [Line Items] | ||
Derivative liability, fair value | 56 | 2 |
Designated as Hedging Instrument | Interest rate contract | Prepaid expenses and other | ||
Derivatives, Fair Value [Line Items] | ||
Derivative asset, fair value | 1 | |
Designated as Hedging Instrument | Interest rate contract | Other Long -Term Assets | ||
Derivatives, Fair Value [Line Items] | ||
Derivative asset, fair value | 136 | 89 |
Designated as Hedging Instrument | Foreign exchange contract | Prepaid expenses and other | ||
Derivatives, Fair Value [Line Items] | ||
Derivative asset, fair value | 79 | 51 |
Not Designated as Hedging Instrument | Foreign exchange contract | Accounts Payable And Accrued Liabilities | ||
Derivatives, Fair Value [Line Items] | ||
Derivative liability, fair value | $2 | $23 |
Derivative_Positions_Presented
Derivative Positions Presented On Net Basis (Detail) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Millions, unless otherwise specified | ||
Derivatives, Fair Value [Line Items] | ||
Gross amounts recognized in the consolidated balance sheet, asset | $215 | $141 |
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, asset | -58 | -22 |
Total | 157 | 119 |
Gross amounts recognized in the consolidated balance sheet, liability | 58 | 25 |
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, liability | -58 | -22 |
Total | $3 |
Financial_Assets_and_Liabiliti
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Millions, unless otherwise specified | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Foreign currency hedges, assets at fair value | $215 | $141 |
Equity securities | 120 | 105 |
Foreign currency hedges, liabilities at fair value | 58 | 25 |
Fair Value, Measurements, Recurring | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Foreign currency hedges, assets at fair value | 79 | 51 |
Interest rate hedges, assets at fair value | 136 | 90 |
Equity securities | 120 | 105 |
Foreign government debt securities | 15 | 18 |
Total assets | 350 | 264 |
Foreign currency hedges, liabilities at fair value | 2 | 23 |
Interest rate hedges, liabilities at fair value | 56 | 2 |
Contingent payments related to acquisitions | 541 | 569 |
Total liabilities | 599 | 594 |
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Equity securities | 120 | 105 |
Total assets | 120 | 105 |
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Foreign currency hedges, assets at fair value | 79 | 51 |
Interest rate hedges, assets at fair value | 136 | 90 |
Foreign government debt securities | 15 | 18 |
Total assets | 230 | 159 |
Foreign currency hedges, liabilities at fair value | 2 | 23 |
Interest rate hedges, liabilities at fair value | 56 | 2 |
Total liabilities | 58 | 25 |
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Contingent payments related to acquisitions | 541 | 569 |
Total liabilities | $541 | $569 |
Book_Values_and_Fair_Values_of
Book Values and Fair Values of Financial Instruments (Detail) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Millions, unless otherwise specified | ||
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items] | ||
Current maturities of long-term debt and lease obligations | $174 | $786 |
Long-term debt and lease obligations | 7,680 | 7,606 |
Book Values | ||
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items] | ||
Investments | 59 | 54 |
Short-term debt | 2,151 | 913 |
Current maturities of long-term debt and lease obligations | 174 | 786 |
Long-term debt and lease obligations | 7,680 | 7,606 |
Long-term litigation liabilities | 48 | 53 |
Approximate fair values | ||
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items] | ||
Investments | 59 | 52 |
Short-term debt | 2,151 | 913 |
Current maturities of long-term debt and lease obligations | 174 | 791 |
Long-term debt and lease obligations | 8,235 | 8,192 |
Long-term litigation liabilities | $47 | $52 |
Summarization_of_Bases_Used_to
Summarization of Bases Used to Measure Fair Value of Financial Instruments (Detail) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Millions, unless otherwise specified | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Current maturities of long-term debt and lease obligations | $174 | $786 |
Long-term debt and lease obligations | 7,680 | 7,606 |
Approximate fair values | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Investments | 59 | 52 |
Total assets | 59 | 52 |
Short-term debt | 2,151 | 913 |
Current maturities of long-term debt and lease obligations | 174 | 791 |
Long-term debt and lease obligations | 8,235 | 8,192 |
Long-term litigation liabilities | 47 | 52 |
Total liabilities | 10,607 | 9,948 |
Fair Value, Inputs, Level 2 | Approximate fair values | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Investments | 10 | 8 |
Total assets | 10 | 8 |
Short-term debt | 2,151 | 913 |
Current maturities of long-term debt and lease obligations | 174 | 791 |
Long-term debt and lease obligations | 8,235 | 8,192 |
Total liabilities | 10,560 | 9,896 |
Fair Value, Inputs, Level 3 | Approximate fair values | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Investments | 49 | 44 |
Total assets | 49 | 44 |
Long-term litigation liabilities | 47 | 52 |
Total liabilities | $47 | $52 |
Stock_Compensation_Additional_
Stock Compensation - Additional Information (Detail) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock compensation expense | $39 | $31 |
Stock based compensation in marketing and administrative expenses | 70.00% | 70.00% |
Stock Options granted | 8.8 | |
Restricted Stock Units | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Awards Granted | 1.3 | |
Unrecognized compensation cost related to all unvested | 154 | |
Weighted-average period for all unvested | 2 years 1 month 6 days | |
Employee Stock Option | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total intrinsic value of stock options exercised | 14 | 45 |
Unrecognized compensation cost related to all unvested | 120 | |
Weighted-average period for all unvested | 2 years 1 month 6 days | |
Performance Shares | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Unrecognized compensation cost related to all unvested | $17 | |
Weighted-average period for all unvested | 1 year 2 months 12 days |
Stock_Options_Fair_Value_Assum
Stock Options Fair Value Assumptions (Detail) (Employee Stock Option, USD $) | 3 Months Ended | |
Mar. 31, 2015 | Mar. 31, 2014 | |
Employee Stock Option | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected volatility | 20.00% | 24.00% |
Expected life (in years) | 5 years 6 months | 5 years 6 months |
Risk-free interest rate | 1.70% | 1.70% |
Dividend yield | 3.00% | 2.80% |
Fair value per stock option | $9 | $12 |
Net_Periodic_Benefit_Cost_Deta
Net Periodic Benefit Cost (Detail) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Pension Plans, Defined Benefit | ||
Net periodic benefit cost | ||
Service cost | $37 | $33 |
Interest cost | 55 | 60 |
Expected return on plan assets | -67 | -66 |
Amortization of net loss and prior service credit/other deferred amounts | 51 | 36 |
Net periodic benefit cost | 76 | 63 |
Other Postretirement Benefit Plans, Defined Benefit | ||
Net periodic benefit cost | ||
Service cost | 1 | 1 |
Interest cost | 6 | 7 |
Amortization of net loss and prior service credit/other deferred amounts | -1 | |
Net periodic benefit cost | $6 | $8 |
Shareholders_Equity_Additional
Shareholders' Equity - Additional Information (Detail) (USD $) | 3 Months Ended | |
In Billions, except Share data, unless otherwise specified | Mar. 31, 2015 | Jul. 31, 2012 |
Stockholders Equity Note [Line Items] | ||
Stock repurchase program, authorized amount | $2 | |
Share repurchases | 0 | |
Remaining value available under stock repurchase programs | $0.50 |
Summary_of_Changes_in_AOCI_by_
Summary of Changes in AOCI by Component (Detail) (USD $) | 3 Months Ended | |||
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 | ||
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] | ||||
Currency translation adjustment, Beginning Balance | ($2,323) | ($991) | ||
Currency translation adjustment, other comprehensive income (loss) before reclassifications | -1,138 | 6 | ||
Currency translation adjustment, amounts reclassified from AOCI | 0 | [1] | 0 | [1] |
Currency translation adjustment, net other comprehensive (loss) income | -1,138 | 6 | ||
Currency translation adjustment, Ending Balance | -3,461 | -985 | ||
Pension and other employee benefit, Beginning Balance | -1,427 | -1,027 | ||
Pension and other employee benefit, Other comprehensive income (loss) before reclassifications | 33 | -3 | ||
Pension and other employee benefit, Amounts reclassified from AOCI | 35 | [1],[2] | 26 | [1],[2] |
Pension and other employee benefit, Net other comprehensive (loss) income | 68 | 23 | ||
Pension and other employee benefit, Ending Balance | -1,359 | -1,004 | ||
Hedging activities, Beginning Balance | 34 | 10 | ||
Hedging activities, Other comprehensive income (loss) before reclassifications | 6 | -8 | ||
Hedging activities, Amounts reclassified from AOCI | -16 | [1],[2] | -2 | [1],[2] |
Hedging activities, Net other comprehensive income (loss) | -10 | -10 | ||
Hedging activities, Ending Balance | 24 | |||
Other, Beginning Balance | 66 | 32 | ||
Other, Other comprehensive income (loss) before reclassifications | 14 | 11 | ||
Other, Amounts reclassified from AOCI | 7 | [1],[2] | ||
Other, Net other comprehensive (loss) income | 21 | 11 | ||
Other, Ending Balance | 87 | 43 | ||
Total, Beginning Balance | -3,650 | -1,976 | ||
Total, Other comprehensive income (loss) before reclassifications | -1,085 | 6 | ||
Total, Amounts reclassified from AOCI | 26 | [1],[2] | 24 | [1],[2] |
Total other comprehensive (loss) income, net of tax | -1,059 | 30 | ||
Total, Ending Balance | ($4,709) | ($1,946) | ||
[1] | See table below for details about these reclassifications. | |||
[2] | Amounts in parentheses indicate reductions to net income. |
Summary_of_Amounts_Reclassific
Summary of Amounts Reclassification from AOCI to Net Income (Detail) (USD $) | 3 Months Ended | |||
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 | ||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Gains (losses) on hedging activities reclassified from AOCI to net income, before tax | $25 | [1] | $4 | [1] |
Gains (losses) on hedging activities reclassified from AOCI to net income, tax expense | -9 | [1] | -2 | [1] |
Gains (loss) on hedging activities reclassified from AOCI to net income, net of tax | 16 | [1],[2] | 2 | [1],[2] |
Total reclassification for the period | -26 | [1],[2] | -24 | [1],[2] |
Amortization of pension and other employee benefits items Actuarial losses and other reclassified from AOCI to net income, before tax | -50 | [1] | -36 | [1] |
Amortization of pension and other employee benefits items Actuarial losses and other reclassified from AOCI to net income, tax benefit | 15 | [1] | 10 | [1] |
Amortization of pension and other employee benefits items Actuarial losses and other reclassified from AOCI to net income, net of tax | -35 | [1],[2] | -26 | [1],[2] |
Gains (loss) on available for sale securities reclassified from AOCI to net income, before tax | -9 | [1] | ||
Gains (loss) on available for sale securities reclassified from AOCI to net income, tax benefit | 2 | [1] | ||
Other Available-for-sale securities reclassified from AOCI to net income, net of tax | -7 | [1],[2] | ||
Other (income) expense, net | Equity securities | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Gains (loss) on available for sale securities Other-than-temporary impairment of reclassified from AOCI to net income, before tax | -9 | [1] | ||
Interest rate contract | Interest Expense | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Gains (losses) on hedging activities reclassified from AOCI to net income, before tax | -1 | [1] | ||
Foreign exchange contract | Cost of Sales | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Gains (losses) on hedging activities reclassified from AOCI to net income, before tax | 25 | [1] | 5 | [1] |
Actuarial losses and other | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Amortization of pension and other employee benefits items Actuarial losses and other reclassified from AOCI to net income, before tax | ($50) | [1],[3] | ($36) | [1],[3] |
[1] | Amounts in parentheses indicate reductions to net income. | |||
[2] | See table below for details about these reclassifications. | |||
[3] | These AOCI components are included in the computation of net periodic benefit cost disclosed in Note 9. |
Income_Taxes_Additional_Inform
Income Taxes - Additional Information (Detail) | 3 Months Ended | |
Mar. 31, 2015 | Mar. 31, 2014 | |
Income Taxes [Line Items] | ||
Effective income tax rate for continuing operations | 20.80% | 22.40% |
Legal_Proceedings_Additional_I
Legal Proceedings - Additional Information (Detail) (USD $) | Mar. 31, 2015 |
In Millions, unless otherwise specified | |
Loss Contingencies [Line Items] | |
Litigation reserve | $64 |
Other Litigation Cases | |
Loss Contingencies [Line Items] | |
Number of derivative actions filed in state court | 2 |
Illinois State | |
Loss Contingencies [Line Items] | |
Number of derivative actions filed in state court | 1 |
Delaware | |
Loss Contingencies [Line Items] | |
Number of derivative actions filed in state court | 1 |
Segment_Information_Additional
Segment Information - Additional Information (Detail) | 3 Months Ended |
Mar. 31, 2015 | |
Segment | |
Segment Information [Line Items] | |
Number of segments | 2 |
Segment_Information_Detail
Segment Information (Detail) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Segment Information [Line Items] | ||
Net sales | $3,764 | $3,848 |
Pre-tax income from continuing operations | 530 | 653 |
BioScience | ||
Segment Information [Line Items] | ||
Net sales | 1,361 | 1,329 |
Pre-tax income from continuing operations | 436 | 484 |
Medical Products | ||
Segment Information [Line Items] | ||
Net sales | 2,403 | 2,519 |
Pre-tax income from continuing operations | 272 | 342 |
Operating Segments | ||
Segment Information [Line Items] | ||
Pre-tax income from continuing operations | $708 | $826 |
Segment_Information_Related_to
Segment Information Related to Total Assets (Detail) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Millions, unless otherwise specified | ||
Segment Reporting, Asset Reconciling Item [Line Items] | ||
Total assets | $24,861 | $25,917 |
BioScience | ||
Segment Reporting, Asset Reconciling Item [Line Items] | ||
Total assets | 9,379 | 9,312 |
Medical Products | ||
Segment Reporting, Asset Reconciling Item [Line Items] | ||
Total assets | 11,316 | 12,064 |
Other | ||
Segment Reporting, Asset Reconciling Item [Line Items] | ||
Total assets | $4,166 | $4,541 |
Pre_Tax_Income_Reconciliation_
Pre- Tax Income Reconciliation (Detail) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||
Consolidated income before income taxes | $530 | $653 |
Operating Segments | ||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||
Consolidated income before income taxes | 708 | 826 |
Unallocated Amount To Segment Stock Compensation | ||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||
Consolidated income before income taxes | -39 | -31 |
Unallocated Amount To Segment Net Interest Expense | ||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||
Consolidated income before income taxes | -30 | -43 |
Unallocated Amount To Segment Business Optimization Items | ||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||
Consolidated income before income taxes | 11 | -20 |
Unallocated Amount To Segment Certain Foreign Currency Fluctuations and Hedging Activities | ||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||
Consolidated income before income taxes | 115 | 16 |
Unallocated Amount to Segment Other Corporate Items | ||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||
Consolidated income before income taxes | ($235) | ($95) |